Beta-amino acid compounds as integrin antagonists

ABSTRACT

The present invention relates to compounds of the general formula (I),  
                 
 
     wherein the residues R represent organic radicals, X represents a bond, oxygen or —NR 12  and Y represents oxygen or sulfur, processes for their preparation, pharmaceutical compositions containing them as well as their use for the production of pharmaceutical compositions for the treatment of inflammatory, autoimmune and immune diseases.

[0001] The present invention relates to compounds of formula (I),

[0002] their preparation and use as pharmaceutical compositions as integrin antagonists, especially as α₄β₁ and/or α₄β₇ and/or α₉β₇ integrin antagonists and in particular for the production of pharmaceutical compositions suitable for the inhibiton or the prevention of cell adhesion and cell-adhesion mediated disorders. Examples are the treatment and the prophylaxis of arteriosclerosis, asthma, allergies, diabetes, inflammatory bowel disease, multiple sclerosis, myocardial ischemia, rheumatoid arthritis, transplant rejection and other inflammatory, autoimmune and immune disorders.

[0003] Adhesive interactions between the leukocytes and endothelial cells play a critical role in leukocyte trafficking to sites of inflammation. These events are essential for normal host defense against pathogens and repair of tissue damage, but can also contribute to the pathology of a variety of inflammatory and autoimmune disorders. Indeed, eosinophil and T cell infiltration into the tissue is known as a cardinal feature of allergic inflammation such as asthma.

[0004] The interaction of circulating leukocytes with adhesion molecules on the luminal surface of blood vessels appears to modulate leukocyte transmigration. These vascular cell adhesion molecules arrest circulating leukocytes, thereby serving as the first step in their recruitment to infected or inflamed tissue sites. Subsequently, the leukocytes reaching the extravascular space interact with connective tissue cells such as fibroblasts as well as extracellular matrix proteins such as fibronectin, laminin, and collagen. Adhesion molecules on the leukocytes and on the vascular endothelium are hence essential to leukocyte migration and attractive therapeutic targets for intervention in many inflammatory disorders.

[0005] Leukocyte recruitment to sites of inflammation occurs in a stepwise fashion beginning with leukocyte tethering to the endothelial cells lining the blood vessels. This is followed by leukocyte rolling, activation, firm adhesion, and transmigration. A number of cell adhesion molecules involved in the those four recruitment steps have been identified and characterized to date. Among them, the interaction between

[0006] VCAM-1 and VLA-4 has been shown to mediate the tethering, rolling, and adhesion of lymphocytes and eosinophils, but not neutrophils, to endothelial cells under a physiologic flow condition. This suggests that the interaction between VCAM-1 and VLA-4 could predominantly mediate a selective recruitment of leukocyte sub-populations in vivo. The inhibition of this interaction is a point of departure for therapeutic intervention.

[0007] VCAM-1 is a member of immunoglobulin (Ig) superfamily and is one of the key regulators of leukocyte trafficking to sites of inflammation. VCAM-1, along with ICAM-1 and E-selectin, is expressed on inflamed endothelium activated by such cytokines as IL-1 and TNF-α, as well as by LPS, via NF-KB dependent pathway. However, these molecules are not expressed on resting endothelium. Cell adhesion mediated by VCAM-1 may be involved in numerous physiological and pathological processes including myogenesis, hematopoiesis, inflammatory reactions, and the development of autoimmune disorders. Integrins VLA-4 and α4β7 both function as leukocyte receptors for VCAM-1.

[0008] The integrin α₄β₁ (VLA-4) is a heterodimeric protein expressed in substantial levels on all circulating leukocytes except mature neutrophils. It regulates cell migration into tissues during inflammatory responses and normal lymphocyte trafficking. VLA-4 binds to different primary sequence determinants, such as a QIDSP motif of VCAM-1 and a ILDVP sequence of the major cell type-specific adhesion site of the alternatively spliced type HI connecting segment domain (CS-1) of fibronectin.

[0009] In vivo studies with neutralizing monoclonal antibodies and inhibitor peptides have demonstrated a critical role for α4 integrins interaction in leukocyte-mediated inflammation. Blocking of VLA-4/ligand interactions, thus, holds promise for therapeutic intervention in a variety of inflammatory, autoimmune and immune diseases (Zimmerman, C.; Exp. Opin. Ther. Patents 1999, 9, 129-133).

[0010] Natural ligands for integrin receptors are for example extracellular matrix proteins such as fibronectin, laminin and collagen containing a specific binding sequence. In case of the α₄β₁, integrin receptor LDV is the specific binding sequence of the natural protein ligands (LDV is the single letter code for the α-amino acid sequence leucine-aspartate-valine [N-terminus→C-terminus]). The most important structural feature for binding is the free carboxylic acid group of the aspartate. Thus, synthetic inhibitors have to mimic the natural binding sequence including a free carboxylic acid group.

[0011] Accordingly, compounds containing a dipeptide with a free carboxylic acid C-terminus as structural element were disclosed as α₄β₁ integrin receptor antagonists, such as WO 98/53817 discloses prolin-β-phenylalanin [N-terminus→C-terminus] derivatives, WO 98/26921 discloses prolin-β-phenylalanin [N-terminus→C-terminus] derivatives and WO 99/25685 discloses isonipecotic acid (a cyclic γ-amino acid)-phenylalanin [N-terminus→C-terminus] derivatives substituted with a bisarylurea. However, no dipeptide derivatives with a 3-amino acid as N-terminus have been described.

[0012] β-amino acids have been shown to stabilise helices [D. Seebach, P. E. Ciceri, M. Overhand, B. Jaun, D. Rigo, L. Oberer, U, Hommel, R. Amstutz, H. Widmer Helv. Chim. Acta 1996, 79, 2043-66] and sheet-structures [S. Krauthäuser, L. A. Christianson, D. R. Powell, S. Gellman J. Am. Chem. Soc. 1997, 119, 11719-20] which are completely different from regular secundary structural elements like α-helices or β-sheets which are observed for α-amino acids. Thus β-amino acids show a conformational behavior which is significantly different from natural α-amino acids and it cannot be expected that generally aβ-amino acids will mimic corresponding α-amino acids. Consequently, the replacement of a α-amino acid within a biologically active compound containing a peptidic substructure against a β-amino acid will generally disturb the bioactive conformation, yielding compounds with significantly decreased activity.

[0013] Surprisingly, however, in the present invention it has now been found that β-amino acid derivatives of formula (I) are potent integrin antagonists, especially α₄β₁ integrin antagonists.

[0014] An object of the present invention is to provide new, alternative, β-amino acid derived integrin antagonists for the treatment of inflammatory, autoimmune and immune diseases.

[0015] The present invention therefore relates to compounds of the general formula (I):

[0016] wherein

[0017] R¹ represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R¹⁰, and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-C₉ heteroaryl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R¹⁰,

[0018] wherein

[0019] R¹⁰ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR¹¹, —SR¹¹, NR¹³R¹⁴, —C(O)R¹¹, S(O)R¹¹, —SO₂R¹¹, —CO₂R¹¹, —OC(O)R¹¹, —C(O)NR¹³R¹⁴, —NR¹¹C(O)R¹¹, —SO₂NR¹³R¹⁴, NR¹¹SO₂R¹¹, —NR¹¹C(O)NR¹³R¹⁴, —NR¹¹C(O)OR¹¹, —OC(O)NR¹³R¹⁴, halogen, cyano, nitro or oxo,

[0020] wherein

[0021] R¹¹ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and

[0022] wherein

[0023] R¹³ and R¹⁴ are identical or different and represent hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl,

[0024] or

[0025] R¹³ and R¹⁴ together form a 4-7-membered ring, which includes the nitrogen atom to which R¹³ and R¹⁴ are bonded and which contains up to 2 additional hetero-atoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds,

[0026] R² represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R¹⁵, and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-Cg heteroaryl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R¹⁵,

[0027] wherein

[0028] R¹⁵ represents C₁₋₄ alkyl, trifluormethyl, trifluornethoxy, —OR¹⁶, —SR⁶, NR¹⁷R¹⁸, —C(O)R¹⁶, S(O)R¹⁶, —SO₂R¹⁶, —CO₂R¹⁶, —OC(O)R¹⁶, —C(O)NR¹⁷R¹⁸, —NR¹⁶C(O)R¹⁶, —SO₂NR¹⁷R¹⁸, NR¹⁶SO₂R⁶, —NR¹⁶C(O)NR¹⁷R¹⁸, —NR¹⁶C(O)OR¹⁶, —OC(O)NR¹⁷R¹⁸, halogen, cyano, nitro or oxo,

[0029] wherein

[0030] R¹⁶ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and

[0031] wherein

[0032] R¹⁷ and R¹⁸ are identical or different and represent hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl,

[0033] or

[0034] R¹⁷ and R¹⁸ together form a 4-7-membered ring, which includes the nitrogen atom to which R¹⁷ and R¹⁸ are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds,

[0035] R³ represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R¹⁹, and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-Cg heteroaryl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R¹⁹,

[0036] wherein

[0037] R¹⁹ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR²⁰, —SR²⁰, NR²¹R²², —C(O)R²⁰, S(O)R²⁰, —SO₂R²⁰, —CO₂R²⁰, —OC(O)R²⁰, —C(O)NR²¹ R²², —NR²⁰C(O)R²⁰, —SO₂NR²¹R²², NR²⁰SO₂R²⁰, —NR²⁰C(O)NR²¹R²², —NR²⁰C(O)OR²⁰, —OC(O)NR²¹R²², halogen, cyano, nitro or oxo,

[0038] wherein

[0039] R²⁰ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl,

[0040] which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and

[0041] wherein

[0042] R²¹ and R²² are identical or different and represent hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl, or

[0043] R² and R²² together form a 4-7-membered ring, which includes the nitrogen atom to which R²¹ and R²² are bonded and which contains up to 2 additional hetero-atoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds,

[0044] R⁴ represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R²³, and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-C₉ heteroaryl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R²³, wherein

[0045] R²³ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR²⁴, —SR²⁴, NR²⁵R²⁶, —C(O)R²⁴, S(O)R²⁴, —SO₂R²⁴—CO₂R²⁴, —OC(O)R²⁴2-C(O)NR²⁵R²⁶, —NR²⁴C(O)R²⁴, —SO₂NR²⁵R²⁶, NR²⁴SO₂R²⁴, —NR²⁴C(O)NR²⁵R²⁶, —NR²⁴C(O)OR²⁴, —OC(O)NR²⁵R²⁶, halogen, cyano, nitro or oxo,

[0046] wherein

[0047] R²⁴ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and

[0048] wherein

[0049] R²⁵ and R²⁶ are identical or different and represent hydrogen, C₁₋₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl,

[0050] or

[0051] R²⁵ and R²⁶ together form a 4-7-membered ring, which includes the nitrogen atom to which R²⁵ and R²⁶ are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds,

[0052] R⁵ represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R²⁷, and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-C₉ heteroaryl or a heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R²⁷,

[0053] wherein

[0054] R²⁷ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR²⁸, —SR²⁸, NR²⁹R³⁰—C(O)R²⁸, —S(O)R²⁸, —SO₂R²⁸, —CO₂R²⁸, —OC(O)R²⁸, —C(O)NR²⁹R³⁰, —NR²⁸C(O)R²⁸, —SO₂NR²⁹R³⁰, NR²⁸ SO₂R²⁸, —NR²⁸C(O)NR²⁹R³⁰, —NR²⁸C(O)OR²⁸, —OC(O)NR²⁹R³⁰, halogen, cyano, nitro or oxo, wherein

[0055] R²⁸ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and wherein R²⁹ and R³⁰ are identical or different and represent hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl, or

[0056] R²⁹ and R³⁰ together form a 4-7-membered ring, which includes the nitrogen atom to which R²⁹ and R³⁰ are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds,

[0057] R⁶ represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R³¹ and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-Cg heteroaryl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, or be benzo-fused, which can optionally be substituted by 1 to 3 radicals R³¹, wherein

[0058] R³¹ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR³², —SR^(32 NR) ³³R³⁴, —C(O)R³², S(O)R³², —SO₂R³², —CO₂R³², —OC(O)R³², —C(O)NR³³R³⁴, —NR³²C(O)R³², —SO₂NR³³R³⁴ NR³²SO₂R³², —NR³²C(O)NR³³R³⁴—NR³²C(O)OR³², —OC(O)NR³³R³⁴, halogen, cyano, nitro or oxo,

[0059] wherein

[0060] R³² represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 to 3 substituents selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano,

[0061] and wherein R³³ and R³⁴ are identical or different and represent hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano,

[0062] or

[0063] R³³ and R³⁴ together form a 4-7-membered ring, which includes the nitrogen atom to which R³³ and R³⁴ are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds, which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, benzyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano, oxo,

[0064] R⁷ represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R³⁵, and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-C₉ heteroaryl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R³⁵,

[0065] wherein

[0066] R³⁵ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR³⁶, —SR³⁶, NR³⁷R³⁸, —C(O)R³⁶, S(O)R³⁶, —SO₂R³⁶, —CO₂R³⁶, —OC(O)R³⁶, —C(O)NR³⁷R³⁸, —NR³⁶C(O)R³⁶, —SO₂NR³⁷R³⁸, NR³⁶SO₂R³⁶—NR³⁶C(O)NR³⁷R³⁸—NR³⁶C(O)OR³⁶, —OC(O)NR³⁷R³⁸, halogen, cyano, nitro or oxo,

[0067] wherein

[0068] R³⁶ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and wherein R³⁷ and R³⁸ are identical or different and represent hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl,

[0069] or

[0070] R³⁷ and R³⁸ together form a 4-7-membered ring, which includes the nitrogen atom to which R³⁷ and R³⁸ are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds,

[0071] R⁸ represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R³⁹, and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-Cg heteroaryl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R³⁹, wherein

[0072] R³⁹ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR⁴⁰, —SR⁴⁰, NR⁴¹R⁴², —C(O)R⁴⁰, S(O)R⁴⁰, —SO₂R⁴⁰, —CO₂R⁴⁰, —OC(O)R⁴⁰, —C(O)NR⁴¹R⁴², —NR⁴⁰C(O)R⁴⁰, —SO₂NR⁴¹R⁴², NR⁴⁰SO₂R⁴⁰, —NR⁴⁰C(O)NR⁴¹R⁴², —NR⁴⁰C(O)OR⁴⁰, —OC(O)NR⁴¹R⁴², halogen, cyano, nitro or oxo,

[0073] wherein

[0074] R⁴⁰ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano,

[0075] and wherein R⁴¹ and R⁴² are identical or different and represent hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl,

[0076] or

[0077] R⁴¹ and R⁴² together form a 4-7-membered ring, which includes the nitrogen atom to which R⁴¹ and R⁴² are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds,

[0078] R⁹ represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-Cg heteroaryl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R⁴³, and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-C₉ heteroaryl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R⁴³,

[0079] wherein

[0080] R⁴³ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR⁴⁴, —SR⁴⁴, NR⁴⁵R⁴⁶, —C(O)R⁴⁴, S(O)R⁴⁴, —SO₂R⁴⁴, —CO₂R⁴⁴, —OC(O)R⁴⁴, —C(O)NR⁴⁵R⁴⁶, —NR⁴⁴C(O)R⁴⁴, —SO₂NR⁴⁵R⁴⁶, NR⁴⁴SO₂R⁴⁴, —NR⁴⁴C(O)NR⁴¹R⁴⁶, —NR⁴⁴C(O)OR⁴⁴, —OC(O)NR⁴⁵R⁴⁶, halogen, cyano, tetrazolyl, nitro or oxo,

[0081] wherein

[0082] R⁴⁴ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano,

[0083] and wherein R⁴⁵ and R⁴⁶ are identical or different and represent hydrogen, C₁-C₁₀ alkyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can furthermore be substituted by C₁-C₁₀ alkyl, C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, benzyl diphenylmethyl, C₄-Cg heteroaryl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 hetero-atoms selected from the group oxygen, nitrogen or sulfur,

[0084] or

[0085] R⁴⁵ and R⁴⁶ together form a 4-7-membered ring, which includes the nitrogen atom to which R⁴⁵ and R⁴⁶ are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds, which can furthermore be substituted by C₁-C₁₀ alkyl, C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, benzyl, diphenylmethyl, C₄-Cg heteroaryl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can be fused with a 3-7 membered homocyclic or heterocyclic, saturated or unsaturated ring,

[0086] or

[0087] R¹ and R² or R⁴ and R² or R⁶ and R¹² together form a 4-7-membered ring, which includes the nitrogen atom to which R² or R⁶ and R¹² can be attached and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and containing up to 2 double bonds, and which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, benzyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano, oxo, and which can be fused with a 3-7 membered homocyclic or heterocyclic, saturated or unsaturated ring,

[0088] or

[0089] R¹ and R⁴ or R¹ and R⁵ or R³ and R⁴ together form a 4-7-membered ring containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur and containing up to 2 double bonds, which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, benzyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano, oxo and which can be fused with a 3-7 membered homocyclic or heterocyclic, saturated or unsaturated ring,

[0090] A represents —C(O)—, —C(O)—C(O)—, —C(S)—, —SO—, —SO₂—, —PO—, —PO₂—, 2-pyrimidyl, 4-pyrimidyl, 2-pyridyl, 2-imidazolyl, 4-imidazolyl, 2-benzimidazolyl or a ring selected from the following group:

[0091] wherein the abovementioned ring systems can optionally be substituted by C₁-C₄ alkyl, C₁-C₄ alkoxy, halogen, nitro, cyano,

[0092] X represents a bond, oxygen or —NR¹²,

[0093] wherein

[0094] R¹² represents hydrogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl which can be optionally substituted by phenyl,

[0095] or

[0096] together with R⁶ form a 4-7-membered ring, which includes the nitrogen atom to which R⁶ and R¹² can be attached and which can contain up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and containing up to 2 double bonds, which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, benzyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano, oxo,

[0097] Y represents oxygen or sulfur,

[0098] Z represents —C(O)OR⁴⁷, —C(O)NR⁴⁸R⁴⁹′, —SO₂NR⁴⁸R⁴⁹, —SO(OR⁴⁷), —SO₂(OR⁴⁷), —P(O)R⁴⁷(OR⁴⁹), —PO(OR⁴⁷)(OR⁴⁹) or 5-tetrazolyl,

[0099] wherein

[0100] R⁴⁸ is —C(O)R⁵⁰ or —SO₂R⁵⁰, wherein

[0101] R⁵⁰ is C₁-C₄ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl, which can optionally be substituted by 1 to 3 substituents selected from the group halogen, nitro, cyano,

[0102] R⁴⁷ and R⁴⁹ are identical or different and represent hydrogen, polymeric resin, C₁-C₄ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl, which can optionally be substituted by 1 to 3 substituents selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano,

[0103] and pharmaceutically acceptable salts thereof.

[0104] A preferred embodiment of the present invention are compounds according the general formula (I),

[0105] wherein

[0106] R¹ represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R¹⁰, and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-Cg heteroaryl or a heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R¹⁰,

[0107] wherein

[0108] R¹⁰ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR¹¹, —SR¹¹ 1 NR¹³R¹⁴, —C(O)R¹¹, S(O)R¹¹, —SO₂R¹¹, —CO₂R¹¹, —OC(O)R¹¹, —C(O)NR¹³ R¹⁴, —NR¹¹C(O)R¹¹, —SO₂NR¹³R¹⁴ NR¹¹SO₂R¹¹, —NR¹¹C(O)NR¹³R¹³, —NR¹⁴C(O)OR¹¹, —OC(O)NR¹³R¹⁴, halogen, cyano, nitro or oxo,

[0109] wherein

[0110] R¹¹ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and

[0111] wherein R¹³ and R¹⁴ are identical or different and represent hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl,

[0112] or

[0113] R¹³ and R¹⁴ together form a 4-7-membered ring, which includes the nitrogen atom to which R¹³ and R¹⁴ are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds,

[0114] R² represents hydrogen, C₁-C₁₀ alkyl C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R¹⁵, and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-C₉ heteroaryl or a heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R¹⁵,

[0115] wherein

[0116] R¹⁵ represents C₁₋₄ alkyl, trifluormethyl, trifluormethoxy, —OR¹⁶, —SR¹⁶ NR¹⁷R¹⁸, —C(O)R¹⁶, S(O)R¹⁶, —SO₂R¹⁶, —CO₂R¹⁶, —OC(O)R¹⁶, —C(O)NR¹⁷R¹⁸, —NR¹⁶C(O)R¹⁶, —SO₂NR¹⁶R¹⁷NR¹⁸ SO₂R¹⁶, —NR¹⁶C(O)NR¹¹R¹⁸, —NR¹⁶C(O)OR¹⁶, —OC(O)NR¹¹R¹⁸, halogen, cyano, nitro or oxo,

[0117] wherein

[0118] R¹⁶ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or COO aryl which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and

[0119] wherein R¹⁷ and R¹⁸ are identical or different and represent hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl, or

[0120] R¹⁷ and R¹⁸ together form a 4-7-membered ring, which includes the nitrogen atom to which R¹⁷ and R¹⁸ are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds,

[0121] R³ represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R¹⁹, and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-Cg heteroaryl or a heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R¹⁹,

[0122] wherein

[0123] R¹⁹ represents C₁-C₄ alkyl, trifluonnethyl, trifluormethoxy, —OR²⁰, —SR²⁰, NR²¹ R²², —C(O)R²⁰, S(O)R²⁰, —SO₂R²⁰, —CO₂R²⁰, —OC(O)R²⁰, —C(O)NR²¹R²², —NR²⁰C(O)R²⁰, —SO₂NR²R²², —NR²⁰SO₂R²⁰, —NR²⁰C(O)NR²¹R²², —NR²⁰C(O)OR²⁰, —OC(O)NR²¹R²², halogen, cyano, nitro or oxo,

[0124] wherein

[0125] R²⁰ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and

[0126] wherein R²¹ and R²² are identical or different and represent hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl,

[0127] or

[0128] R²¹ and R²² together form a 4-7-membered ring, which includes the nitrogen atom to which R²¹ and R²² are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds,

[0129] R⁴ represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R²³, and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-C₁₀ heteroaryl or a heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R²³,

[0130] wherein

[0131] R²³ represents C₁-C₄ alkyl, trifluormethyl, trifluornethoxy, —OR²⁴, —SR²⁴ NR²⁵R²⁶, —C(O)R²⁴, S(O)R²⁴, —SO₂R²⁴, —CO₂R²⁴, —OC(O)R²⁴, —C(O)NR²⁵R²⁶, —NR²⁴C(O)R²⁴, —SO₂NR²⁵ R²⁶, NR²⁴ SOR²⁴, —NR²⁴C(O)NR²⁵R²⁶, —NR²⁴C(O)OR²⁴, —OC(O)NR²⁵R²⁶, halogen, cyano, nitro or oxo,

[0132] wherein

[0133] R²⁴ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and

[0134] wherein

[0135] R²⁵ and R²⁶ are identical or different and represent hydrogen, C₁₋₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl,

[0136] or

[0137] R²⁵ and R²⁶ together form a 4-7-membered ring, which includes the nitrogen atom to which R²⁵ and R²⁶ are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds,

[0138] R⁵ represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R²⁷, and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-C₉ heteroaryl or a heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R²⁷,

[0139] wherein

[0140] R²⁷ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR²⁸, —SR²⁸, NR²⁹R³⁰, —C(O)R²⁸, S(O)R²⁸, —SO₂R²⁸, —CO₂R²⁸, —OC(O)R²⁸, —C(O)NR²⁹R³⁰, —NR²⁸C(O)R²⁸, —SO₂NR²⁹R³⁰, NR²⁸SO₂R²⁸, —NR²⁸C(O)NR²⁹R³⁰, —NR²⁸C(O)OR²⁸, —OC(O)NR²⁹R¹⁰, halogen, cyano, nitro or oxo,

[0141] wherein

[0142] R²⁸ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and

[0143] wherein

[0144] R²⁹ and R³⁰ are identical or different and represent hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl,

[0145] or

[0146] R²⁹ and R³⁰ together form a 4-7-membered ring, which includes the nitrogen atom to which R²⁹ and R³⁰ are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds,

[0147] R⁶ represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R³¹ and which can further-more be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-Cg heteroaryl or a heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, or be benzo-fused, which can optionally be substituted by 1 to 3 radicals R³¹,

[0148] wherein

[0149] R³¹ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR³², —SR³², NR³³R³⁴, —C(O)R³², S(O)R³², —SO₂R³², —CO₂R³², —OC(O)R³, —C(O)NR³³R³⁴, —NR³²C(O)R³², —SO₂NR³³R³⁴, —NR³²SO₂R³², —NR³²C(O)NR³³R³⁴, —NR³²C(O)OR³², —OC(O)NR³³R³⁴, halogen, cyano, nitro or oxo,

[0150] wherein

[0151] R³² represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 to 3 substituents selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and

[0152] wherein

[0153] R³³ and R³⁴ are identical or different and represent hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano,

[0154] or

[0155] R³³ and R³⁴ together form a 4-7-membered ring, which includes the nitrogen atom to which R³³ and R³⁴ are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds, which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, benzyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano, oxo,

[0156] R⁷ represents hydrogen, C₁ C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R³⁵, and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-Cg heteroaryl or a heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R³⁵,

[0157] wherein

[0158] R³⁵ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR³⁶, —SR³⁶, NR³⁷R³⁸ C(O)R³⁶, S(O)R³⁶, —SO₂R³⁶, —CO₂R³⁶, —OC(O)R³⁶, —C(O)NR³⁷R³⁸, —NR³⁶C(O)R³⁶, —SO₂NR³⁷R³⁸, NR³⁶SO₂R³⁶, —NR³⁶C(O)NR³⁷R³, —NR³⁶C(O)OR³⁶, —OC(O)NR³R³⁸, halogen, cyano, nitro or oxo,

[0159] wherein

[0160] R³⁶ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and

[0161] wherein

[0162] R³⁷ and R³⁸ are identical or different and represent hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl,

[0163] or

[0164] R³⁷ and R³⁸ together form a 4-7-membered ring, which includes the nitrogen atom to which R³⁷ and R³⁸ are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds,

[0165] R⁸ represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R³⁹, and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-C₉ heteroaryl or a heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R³⁹,

[0166] wherein

[0167] R³⁹ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR⁴⁰, —SR⁴⁰, NR⁴¹R⁴², —C(O)R⁴⁰, S(O)R⁴⁰, —SO₂R⁴′, —CO₂R⁴⁰, —OC(O)R⁴⁰, —C(O)NR⁴¹R⁴², —NR⁴⁰C(O)R⁴⁰, —SO₂NR⁴¹R⁴2 NR⁴⁰ SO₂R⁴⁰, —NR⁴⁰C(O)NR⁴¹R⁴², —NR⁴⁰C(O)OR⁴⁰, —OC(O)NR⁴R⁴², halogen, cyano, nitro or oxo,

[0168] wherein

[0169] R⁴⁰ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and

[0170] wherein

[0171] R⁴¹ and R⁴² are identical or different and represent hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₀ aryl,

[0172] or

[0173] R⁴¹ and R⁴² together form a 4-7-membered ring, which includes the nitrogen atom to which R⁴¹ and R⁴² are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds,

[0174] R⁹ represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-C₉ heteroaryl or a heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R⁴³, and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-Cg heteroaryl or a heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R⁴³,

[0175] wherein

[0176] R⁴³ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR⁴⁴, —SR⁴⁴, NR⁴⁵R⁴⁶, —C(O)R⁴⁴, S(O)R⁴⁴, —SO₂Re, —CO₂R¹¹, —OC(O)R⁴⁴, —C(O)NR⁴¹R⁴⁶, —NR⁴⁴C(O)R⁴⁴, —SO₂NR⁴⁵R⁴⁶, NR⁴⁴SO₂ R⁴⁴, —NR⁴⁴C(O)NR⁴⁵R⁴⁶, —NR⁴⁴C(O)OR⁴⁴, —OC(O)NR⁴⁵R⁴⁶, halogen, cyano, tetrazolyl, nitro or oxo, wherein R⁴⁴ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and

[0177] wherein

[0178] R⁴⁵ and R⁴⁶ are identical or different and represent hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl,

[0179] or

[0180] R⁴⁵ and R⁴⁶ together form a 4-7-membered ring, which includes the nitrogen atom to which R⁴⁵ and R⁴⁶ are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds,

[0181] or

[0182] R¹ and R² or R⁴ and R² or R⁶ and R¹² together form a 4-7-membered ring, which includes the nitrogen atom to which R² or R⁶ and R¹² can be attached and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and containing up to 2 double bonds, and which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, benzyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano, oxo, and which can be fused with a 3-7 membered homocyclic or heterocyclic, saturated or unsaturated ring,

[0183] or

[0184] R¹ and R⁴ or R¹ and R⁵ or R³ and R⁴ together form a 4-7-membered ring containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur and containing up to 2 double bonds, which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, benzyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano, oxo and which can be fused with a 3-7 membered homocyclic or heterocyclic, saturated or unsaturated ring,

[0185] A represents —C(O)—, —C(O)—C(O)—, —C(S)—, —SO—, —SO₂—, —PO—, —PO₂—, 2-pyrimidyl, 4-pyrimidyl, 2-pyridyl, 2-imidazolyl, 4-imidazolyl, 2-benzimidazolyl or a ring selected from the following group:

[0186] wherein the abovementioned ring systems can optionally be substituted by C₁-C₄ alkyl, C₁-C₄ alkoxy, halogen, nitro, cyano,

[0187] X represents a bond, oxygen or —NR¹²,

[0188] wherein

[0189] R¹² represents hydrogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl which can be optionally substituted by phenyl,

[0190] or

[0191] together with R⁶ form a 4-7-membered ring, which includes the nitrogen atom to which R⁶ and R¹² can be attached and which can contain up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and containing up to 2 double bonds, which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, benzyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano, oxo,

[0192] Y represents oxygen or sulfur,

[0193] Z represents —C(O)OR⁴⁷, —C(O)NR⁴⁸R⁴⁹, —SO₂NR⁴⁸R⁴⁹, —SO(OR⁴⁷), —SO₂(OR⁴⁷), —P(O)R⁴⁷(OR⁴⁹), -PO(OR⁴⁷)(OR⁴⁹) or 5-tetrazolyl,

[0194] wherein

[0195] R⁴⁸ is C(O)R⁵⁰ or —SO₂R¹⁰,

[0196] wherein

[0197] R⁵⁰ is C₁-C₄ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl, which can optionally be substituted by 1 to 3 substituents selected from the group halogen, nitro, cyano,

[0198] R⁴⁷ and R⁴⁹ are identical or different and represent hydrogen, polymeric resin, C₁-C₄ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl, which can optionally be substituted by 1 to 3 substituents selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano,

[0199] and pharmaceutically acceptable salts thereof.

[0200] In another preferred embodiment, the invention relates to compounds of general formula (I)

[0201] wherein

[0202] R¹, R³, R⁴ and R⁵ can be identical or different and represent hydrogen, C₁-C₈ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₆ or C₁₀ aryl, a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, or C₃-C₇ cycloalkyl which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, C₃-C₆ cycloalkyl, trifluormethyl, trifluormethoxy, C₁-C₄ allyloxy, halogen or oxo,

[0203] R² and R⁷ can be identical or different and represent hydrogen, C₁-C₈ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₆ or C₁₀ aryl or C₃-C₇ cycloalkyl wherein all the abovementioned groups can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy

[0204] R⁶ represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R³¹ and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-C₉ heteroaryl or a heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, or benzo-fused, which can optionally be substituted by 1 to 3 radicals R³¹,

[0205] wherein

[0206] R³¹ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR³², —SR³², NR³³R³⁴, —C(O)R³², S(O)R³², —SO₂R³², —CO₂R³², —OC(O)R³², —C(O)NR³³R³⁴, —NR³²C(O)OR³², —OC(O)NR³³R³⁴, NR³²SO₂R³², —NR³²C(O)NR³³R³⁴, —NR³²C(O)OR³², —OC(O)NR³³R³⁴, halogen, cyano, nitro or oxo,

[0207] wherein

[0208] R³² represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 to 3 substituents selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and

[0209] wherein R³³ and R³⁴ are identical or different and represent hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano,

[0210] or

[0211] R³³ and R³⁴ together form a 4-7-membered ring, which includes the nitrogen atom to which R³³ and R³⁴ are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds, which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, benzyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano, oxo,

[0212] R⁸ represents hydrogen, C₁-C₈ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, wherein all the abovementioned groups can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy,

[0213] R⁹ represents hydrogen, C₁-C₄ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₆ or C₁₀ aryl or C₃₋₇ cycloalkyl which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-Cg heteroaryl containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-Cg heteroaryl containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, wherein the latter cyclic group can optionally be substituted by 1 to 3 substituents selected from R⁴³

[0214] wherein

[0215] R⁴³ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR⁴⁴, —SR⁴⁴, NR¹R⁴′, —C(O)R⁴⁴, —SO₂R⁴⁴, —OC(O)R⁴⁴, —C(O)NR⁴⁵R⁴, —NR⁴⁴C(O)R⁴⁴, —SO₂NR⁴ R⁴, NR⁴⁴SO₂R⁴⁴, —NR⁴⁴C(O)NR⁴⁵R⁴⁶, —NR⁴⁴C(O)OR⁴⁴, —OC(O)NR⁴⁵R⁴⁶, halogen, cyano, tetrazolyl, nitro or oxo,

[0216] wherein

[0217] R⁴⁴ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and

[0218] wherein

[0219] R⁴⁵ and R⁴⁶ are identical or different and represent hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl,

[0220] or

[0221] R⁴⁵ and R⁴⁶ together form a 4-7-membered ring, which includes the nitrogen atom to which R⁴⁵ and R⁴⁶ are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds, or

[0222] R¹ and R² or R⁴ and R² or R⁶ and R¹² together form a 5-6-membered ring, which includes the nitrogen atom to which R² or R⁶ and R¹² can be attached and which contains up to 1 additional heteroatom selected from the group oxygen, nitrogen or sulfur and containing up to 2 double bonds, which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, benzyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano, oxo, or which can be fused with a 5-6-membered homocyclic or heterocyclic saturated ring

[0223] or

[0224] R¹ and R⁴ or R¹ and R⁵ or R³ and R⁴ together form a 5-6-membered ring containing up to 1 heteroatom selected from the group oxygen, nitrogen or sulfur and containing up to 2 double bonds, which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, benzyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano, oxo or fused with a 5-6-membered homocyclic or heterocyclic saturated ring

[0225] A represents —C(O)—, —C(O)—C(O)—, —SO—, —SO₂—, —PO—, —PO₂—, 2-pyrimidyl, 4-pyrimidyl, 2-pyridyl, 2-imidazolyl, 4-imidazolyl, 2-benzimidazolyl or a ring selected from the following group:

[0226] wherein the abovementioned ring systems can optionally be substituted by C₁-C₄ alkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano

[0227] X represents a bond, oxygen or —NR¹²,

[0228] wherein

[0229] R¹² represents hydrogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, which can be optionally substituted by phenyl,

[0230] or

[0231] together with R⁶ form a 4-7-membered ring, which includes the nitrogen atom to which R⁶ and R¹² can be attached and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and containing up to 2 double bonds, which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, benzyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano, oxo,

[0232] Y represents oxygen or sulfur,

[0233] Z represents —C(O)OR⁴⁷, —C(O)NR⁴⁸R⁴⁹, —SO₂NR⁴⁸R⁴⁹, —SO(OR⁴⁷), —SO₂(OR⁴⁷), —P(O)R⁴⁷(OR⁴⁹), -PO(OR⁴⁷)(OR⁴⁹) or 5-tetrazolyl,

[0234] wherein

[0235] R⁴⁸ is —C(O)R⁵⁰ or —SO₂R⁵⁰,

[0236] wherein

[0237] R⁵⁰ is C₁-C₄ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl, which can optionally be substituted by 1 to 3 substituents selected from the group halogen, nitro, cyano,

[0238] R⁴⁷ and R⁴⁹ are identical or different and represent hydrogen, polymeric resin, C₁-C₄ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl, which can optionally be substituted by 1 to 3 substituents selected from the group C₁-C₄ alky, C₁-C₄ alkyloxy, halogen, nitro, cyano,

[0239] and pharmaceutically acceptable salts thereof.

[0240] In a particularly preferred embodiment, the invention relates to compounds of general formula (I),

[0241] wherein

[0242] R¹ and R² together form a 6-membered ring, which includes the nitrogen atom to which R² is bonded,

[0243] R³, R⁴, R⁵, R⁷ and R⁸ represent hydrogen,

[0244] R⁶ represents hydrogen, C₁-C₁₀ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl, which can optionally be substituted by 1 to 3 residues selected from the group methyl, methoxy, halogen, carbonyloxymethyl, trifloromethyl and which can furthermore be single-foldedly substituted by C₆ cycloalkyl, phenyl, pyridyl, pyrrolidyl or benzo-fused, which can optionally be substituted by 1 to 3 residues selected from the group methyl, halogen, oxo

[0245] or

[0246] R⁶ and R¹² together form a 6-membered ring, which includes the nitrogen atom to which R⁶ and R¹² can be attached and which contains up to 1 additional heteroatom selected from the group oxygen or nitrogen

[0247] R⁹ represents C, alkyl, which is single-foldedly substituted by C₆ aryl, which is single-foldedly substituted by C₆ aryl, wherein the latter C₆ aryl can optionally be substituted by 1 to 2 substituents selected from the group C, alkyl, C₁ alkyloxy or halogen,

[0248] A represents —C(O)—, —SO₂, −2-pyrimidyl, 4-pyrimidyl, 2-pyridyl or 2-benzimidazolyl, wherein the abovementioned ring systems can optionally be single-foldedly substituted by halogen,

[0249] X represents a bond, oxygen or —NR¹²,

[0250] wherein

[0251] R¹² represents hydrogen, methyl

[0252] or

[0253] together with R⁶ form a 6-membered ring, which includes the nitrogen atom to which R⁶ and R¹² can be attached and which contains up to 1 additional heteroatoms selected from the group oxygen or nitrogen

[0254] Y represents oxygen,

[0255] z represents —C(O)OR⁴⁷,

[0256] wherein

[0257] R⁴⁷ represents hydrogen or polymeric resin,

[0258] and pharmaceutically acceptable salts thereof.

[0259] In a particularly preferred embodiment, the invention relates to the compounds general formula (I)

[0260] wherein

[0261] A represents 2-pyrimidyl, 4-pyrimidyl, 2-pyridyl, 2-benzimidazolyl, wherein the abovementioned ring systems can optionally be substituted by C₁-C₄ alkyl, C₁-C₄ alkoxy, halogen, nitro or cyano.

[0262] In another particularity preferred embodiment, the present invention relates to the compounds according to general formula (I)

[0263] wherein

[0264] A represents —C(O)— or —SO₂

[0265] In a very preferred embodiment, the invention relates to compounds of general formula (I)

[0266] wherein

[0267] R¹, R³, R⁴ and R¹ can be identical or different and represent hydrogen, C₁-C₈ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₆ or C₁₀ aryl, a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, or C₃-C₇ cycloalkyl which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, C₃-C₆ cycloalkyl, trifluormethyl, trifluormethoxy, C₁-C₄ alkyloxy, halogen or oxo,

[0268] R² and R⁷ can be identical or different and represent hydrogen, C₁-C₈ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₆ or C₁₀ aryl or C₃-C₇ cycloalkyl wherein all the abovementioned groups can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy,

[0269] R⁶ represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R³¹ and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-C₉ heteroaryl or a heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, or benzo-fused, which can optionally be substituted by 1 to 3 radicals R³¹,

[0270] wherein

[0271] R³¹ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR³², —SR³²; NR³³R³⁴, —C(O)R³², S(O)R³²—SO₂R³²—CO₂R³²—OC(O)R³²—C(O)NR³³R³⁴, —NR³²C(O)R³², —SO₂NR³³R³⁴, NR³²SO₂R³², —NR³²C(O)NR³³R³⁴, —NR³²C(O)OR³², —OC(O)NR³³R³⁴, halogen, cyano, nitro or oxo,

[0272] wherein

[0273] R³² represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 to 3 substituents selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and

[0274] wherein R³³ and R³⁴ are identical or different and represent hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano,

[0275] or

[0276] R³³ and R³⁴ together form a 4-7-membered ring, which includes the nitrogen atom to which R³³ and R³⁴ are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds, which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, benzyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano, oxo,

[0277] R⁸ represents hydrogen, C₁-C₈ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, wherein all the abovementioned groups can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy,

[0278] R⁹ represents hydrogen, C₁-C₄ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₆ or C₁₀ aryl or C₃₋₇ cycloalkyl which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-Cg heteroaryl containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, wherein the latter cyclic group can optionally be substituted by 1 to 3 substituents selected from R⁴³,

[0279] wherein

[0280] R⁴³ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR⁴⁴, —SR⁴⁴, NR⁴⁵R⁴⁶, —C(O)R⁴⁴, S(O)R⁴⁴, —SO₂R⁴⁴, —CO₂R⁴⁴, —OC(O)R⁴⁴, —C(O)NR⁴⁵R⁴⁶, —NR⁴⁴C(O)R⁴⁴, —SO₂NR⁴R⁴⁶, NR⁴⁴SO₂R⁴⁴, —NR⁴⁴C(O)NR⁴R⁴⁶, —NR⁴⁴C(O)OR⁴⁴, —OC(O)NR⁴⁵R⁴⁶, halogen, cyano, tetrazolyl, nitro or oxo,

[0281] wherein

[0282] R⁴⁴ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and

[0283] wherein

[0284] R⁴⁵ and R⁴⁶ are identical or different and represent hydrogen C₁-C₁₀ alkyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can furthermore be substituted by C₁-C₁₀ alkyl, C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, benzyl, diphenylmethyl, C₄-C₉ heteroaryl or a heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur,

[0285] or

[0286] R⁴⁵ and R⁴⁶ together form a 4-7-membered ring, which includes the nitrogen atom to which R⁴⁵ and R⁴⁶ are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds, which can furthermore be substituted by C₁-C₁₀ alkyl, C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, benzyl, diphenylmethyl, C₄-Cg heteroaryl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can be fused with a 3-7 membered homocyclic or heterocyclic, saturated or unsaturated ring, or

[0287] R¹ and R² or R⁴ and R² or R⁶ and R¹² together form a 5-6-membered ring, which includes the nitrogen atom to which R² or R⁶ and R¹² can be attached and which contains up to 1 additional heteroatom selected from the group oxygen, nitrogen or sulfur and containing up to 2 double bonds, which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, benzyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano, oxo, or which can be fused with a 5-6-membered homocyclic or heterocyclic saturated ring,

[0288] or

[0289] R¹ and R⁴ or R¹ and R⁵ or R³ and R⁴ together form a 5-6-membered ring containing up to 1 heteroatom selected from the group oxygen, nitrogen or sulfur and containing up to 2 double bonds, which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, benzyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano, oxo or fused with a 5-6-membered homocyclic or heterocyclic saturated ring,

[0290] A represents —C(O)—, —C(O)—C(O)—, —SO—, —SO₂—, —PO—, —PO₂—, 2-pyrimidyl, 4-pyrimidyl, 2-pyridyl, 2-imidazolyl, 4-imidazolyl, 2-benzimidazolyl or a ring selected from the following group:

[0291] wherein the abovementioned ring systems can optionally be substituted by C₁-C₄ alkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano

[0292] X represents a bond, oxygen or —NR¹²,

[0293] wherein

[0294] R¹² represents hydrogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, C₂-C₄ alkynyl, which can be optionally substituted by phenyl,

[0295] or

[0296] together with R⁶ form a 4-7-membered ring, which includes the nitrogen atom to which R⁶ and R¹² can be attached and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and containing up to 2 double bonds, which can optionally be substituted by 1 to 2 substituents selected from the group C₁-C₄ alkyl, phenyl, benzyl, C₃-C₇ cycloalkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano, oxo,

[0297] Y represents oxygen or sulfur,

[0298] Z represents —C(O)OR⁴⁷, —C(O)NR⁴⁸R⁴⁹, —SO₂NR⁴⁸R⁴⁹, —SO(OR⁴⁷), —SO₂(OR⁴⁷), —P(O)R⁴⁷(OR⁴⁹), -PO(OR⁴⁷)(OR⁴⁹) or 5-tetrazolyl,

[0299] wherein

[0300] R⁴⁸ is —C(O)R⁵⁰ or —SO₂R⁵⁰,

[0301] wherein

[0302] R⁵⁰ is, C₁-C₄ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl, which can optionally be substituted by 1 to 3 substituents selected from the group halogen, nitro, cyano,

[0303] R⁴⁷ and R⁴⁹ are identical or different and represent hydrogen, polymeric resin, C₁-C₄ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl, which can optionally be substituted by 1 to 3 substituents selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, halogen, nitro, cyano,

[0304] and pharmaceutically acceptable salts thereof.

[0305] In another very preferred embodiment, the invention relates to compounds of general formula (I),

[0306] wherein

[0307] R¹ and R² together form a 6-membered ring, which includes the nitrogen atom to which R² is bonded, R³, R⁴, R⁵, R⁷ and R⁸ represent hydrogen, R⁶ represents hydrogen, C₁-C₁₀ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl, which can optionally be substituted by 1 to 3 residues selected from the group methyl, methoxy, halogen, carbonyloxymethyl, trifluoromethyl and which can furthermore be single-foldedly substituted by C₆ cycloalkyl, phenyl, pyridyl, pyrrolidyl or benzo-fused, which can optionally be substituted by 1 to 3 residues selected from the group methyl, halogen, oxo, or

[0308] R⁶ and R¹² together form a 6-membered ring, which includes the nitrogen atom to which R⁶ and R¹² can be attached and which contains up to 1 additional heteroatom selected from the group oxygen or nitrogen,

[0309] R⁹ represents C₁ alkyl, which is single-foldedly substituted by C₆ aryl, which is single-foldedly substituted by R⁴³,

[0310] wherein

[0311] R⁴³ represents —NR⁴⁴(CO)NR⁴⁵R⁴⁶,

[0312] wherein

[0313] R⁴⁴ represents hydrogen and

[0314] wherein

[0315] R⁴⁵ and R⁴⁶ are identical or different and represent hydrogen, C, alkyl or a 6-membered saturated heterocyclic residue containing 0 or 1 nitrogen, which can furthermore be substituted by benzyl or diphenylmethyl,

[0316] or

[0317] R⁴⁵ and R⁴⁶ together form a 6-membered ring, which includes the nitrogen atom to which R⁴⁵ and R⁴⁶ are bonded and which contains up to 1 additional heteroatom selected from the group oxygen or nitrogen, which can furthermore be substituted by C₁ alkyl, phenyl, benzyl, diphenylmethyl, or which can be benzofused,

[0318] A represents —C(O)—, —SO₂, −2-pyrimidyl, 4-pyrimidyl, 2-pyridyl or 2-benzimidazolyl, wherein the abovementioned ring systems can optionally be single-foldedly substituted by halogen,

[0319] X represents a bond, oxygen or —NR¹²,

[0320] wherein

[0321] R¹² represents hydrogen or methyl,

[0322] or

[0323] together with R⁶ forms a 6-membered ring, which includes the nitrogen atom to which R⁶ and R¹² can be attached and which contains up to 1 additional heteroatom selected from the group oxygen or nitrogen,

[0324] Y represents oxygen,

[0325] z represents —C(O)OR⁴⁷,

[0326] wherein

[0327] R⁴⁷ represents hydrogen or polymeric resin,

[0328] and pharmaceutically acceptable salts thereof.

[0329] In a very particularly preferred embodiment, the invention relates to the specific compounds as described in the specification under “examples”.

[0330] In the context of the present invention alkyl stands for a straight-chain or branched alkyl residue, such as methyl, ethyl, n-propyl, iso-propyl, n-pentyl. If not stated otherwise, preferred is C₁-C₁₀ alkyl, very preferred is C₁-C₆ alkyl.

[0331] Alkenyl and alkinyl stand for straight-chain or branched residues containing one or more double or triple bonds, e.g. vinyl, allyl, isopropinyl, ethinyl. If not stated otherwise, preferred is C₁-C₁₀ alkenyl or alkinyl, very preferred is C₁-C₆ alkenyl or alkinyl.

[0332] Cycloalkyl stands for a cyclic alkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. Preferred is C₃-C₇ cycloalkyl.

[0333] Halogen in the context of the present invention stands for fluorine, chlorine, bromine or iodine. If not specified otherwise, chlorine or fluorine are preferred.

[0334] If not further specified, 4-9-membered saturated or unsaturated heterocyclic residue in the context of the present invention represents heteroatom-containing not aromatic, saturated or unsaturated rings containing 1 to 4 heteroatoms selected from O, S and N. Examples for not aromatic rings are: tetrahydrofur-2-yl, tetrahydrofur-3-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolin-1-yl, piperidin-1-yl, piperidin-3-yl, 1,2-dihydropyridin-1-yl, 1,4-dihydropyridin-1-yl, piperazin-1-yl, morpholin-1-yl, azepin-1-yl, 1,4-diazepin-1-yl. Examples for aromatic rings are: pyridyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolicenyl, indolyl, benzo[b]thienyl, benzo[b]furyl, indazolyl, chinolyl, isochinolyl, naphthyridinyl, chinazolinyl.

[0335] If not specified otherwise, ring systems as substituents can be attached to their respective place of attachment via any ring atom, that is any carbon or nitrogen atom.

[0336] If not specified otherwise, in the context of the present invention heteroatom stands preferably for O, S, N or P.

[0337] Annulated or fused describes 1,1- or 1,2-fused ring systems, e.g. Spiro systems or systems with a [0]-bridge. Benzo-fused describes a [0]-bridge, wherein one of the rings is aromatic.

[0338] The polymeric resin for solid phase is preferably a polystyrene resin and in particular a commercially available Wang polystyrene resin.

[0339] Surprisingly, the compounds of the present invention show good integrin antagonistic activity. They are therefore suitable especially as α₄β₁ and/or α₄β₇ and/or α₉β₁ integrin antagonists and in particular for the production of pharmaceutical compositions for the inhibiton or the prevention of cell adhesion and cell-adhesion mediated disorders. Examples are the treatment and the prophylaxis of arteriosclerosis, asthma, allergies, diabetes, inflammatory bowel disease, multiple sclerosis, myocardial ischemia, rheumatoid arthritis, transplant rejection and other inflammatory, autoimmune and immune disorders.

[0340] The integrin antagonists of the invention are useful not only for treatment of the physiological conditions discussed above, but are also useful in such activities as purification of integrins and testing for activity.

[0341] For the treatment of the abovementioned diseases, the compounds according to the invention can exhibit non-systemic or systemic activity, wherein the latter is preferred. To obtain systemic activity the active compounds can be administered, among other things, orally or parenterally, wherein oral administration is preferred.

[0342] For parenteral administration, forms of administration to the mucous membranes (i.e. buccal, lingual, sublingual, rectal, nasal, pulmonary, conjunctival or intravaginal) or into the interior of the body are particularly suitable. Administration can be carried out by avoiding absorption (i.e. intracardiac, intra-arterial, intravenous, intraspinal or intralumbar administration) or by including absorption (i.e. intracutaneous, subcutaneous, percutaneous, intramuscular or intraperitoneal administration).

[0343] For the above purpose the active compounds can be administered per se or in administration forms.

[0344] Suitable administration forms for oral administration are, inter alia, normal and enteric-coated tablets, capsules, coated tablets, pills, granules, pellets, powders, solid and liquid aerosols, syrups, emulsions, suspensions and solutions. Suitable administration forms for parenteral administration are injection and infusion solutions.

[0345] The active compound can be present in the administration forms in concentrations of from 0-100% by weight; preferably the concentration of the active compound should be 0.5-90% by weight, i.e. quantities which are sufficient to allow the specified range of dosage.

[0346] The active compounds can be converted in the known manner into the above-mentioned administration forms using inert non-toxic pharmaceutically suitable auxiliaries, such as for example excipients, solvents, vehicles, emulsifiers and/or dispersants.

[0347] The following auxiliaries can be mentioned as examples: water, solid excipients such as ground natural or synthetic minerals (e.g. talcum or silicates), sugar (e.g. lactose), non-toxic organic solvents such as paraffins, vegetable oils (e.g. sesame oil), alcohols (e.g. ethanol, glycerol), glycols (e.g. polyethylene glycol), emulsifying agents, dispersants (e.g. polyvinylpyrrolidone) and lubricants (e.g. magnesium sulphate).

[0348] In the case of oral administration tablets can of course also contain additives such as sodium citrate as well as additives such as starch, gelatin and the like. Flavour enhancers or colorants can also be added to aqueous preparations for oral administration.

[0349] For the obtainment of effective results in the case of parenteral administration it has generally proven advantageous to administer quantities of about 0.001 to 100 mg/kg, preferably about 0.01 to 1 mg/kg of body weight. In the case of oral administration the quantity is about 0.01 to 100 mg/kg, preferably about 0.1 to 10 mg/kg of body weight.

[0350] It may nevertheless be necessary to use quantities other than those mentioned above, depending on the body weight concerned, the method of administration, the individual response to the active compound, the type of preparation and the time or interval of administration.

[0351] Suitable pharmaceutically acceptable salts of the compounds of the present invention that contain an acidic moiety include addition salts formed with organic or inorganic bases. The salt forming ion derived from such bases can be metal ions, e.g., aluminum, alkali metal ions, such as sodium of potassium, alkaline earth metal ions such as calcium or magnesium, or an amine salt ion, of which a number are known for this purpose. Examples include ammonium salts, arylalkylamines such as dibenzylamine and N,N-dibenzylethylenediamine, lower alkylamines such as methylamine, t-butylamine, procaine, lower alkylpiperidines such as N-ethyl-piperidine, cycloalkylamines such as cyclohexylamine or dicyclohexylamine, 1-adamantylamine, benzathine, or salts derived from amino acids like arginine, lysine or the like. The physiologically acceptable salts such as the sodium or potassium salts and the amino acid salts can be used medicinally as described below and are preferred.

[0352] Suitable pharmaceutically acceptable salts of the compounds of the present invention that contain a basic moiety include addition salts formed with organic or inorganic acids. The salt forming ion derived from such acids can be halide ions or ions of natural or unnatural carboxylic or sulfonic acids, of which a number are known for this purpose. Examples include chlorides, acetates, tartrates, or salts derived from amino acids like glycine or the like. The physiologically acceptable salts such as the chloride salts and the amino acid salts can be used medicinally as described below and are preferred.

[0353] These and other salts which are not necessarily physiologically acceptable are useful in isolating or purifying a product acceptable for the purposes described below.

[0354] The salts are produced by reacting the acid form of the invention compound with an equivalent of the base supplying the desired basic ion or the basic form of the invention compound with an equivalent of the acid supplying the desired acid ion in a medium in which the salt precipitates or in aqueous medium and then lyophilizing. The free acid or basic form of the invention compounds can be obtained from the salt by conventional neutralization techniques, e.g., with potassium bisulfate, hydrochloric acid, sodium hydroxide, sodium bicarbonate, etc.

[0355] The compounds according to the invention can form non covalent addition compounds such as adducts or inclusion compounds like hydrates or clathrates. This is known to the artisan and such compounds are also object of the present invention.

[0356] The compounds according to the invention can exist in different stereoisomeric forms, which relate to each other in an enantiomeric way (image and mirror image) or in a diastereomeric way (image different from mirror image). The invention relates to the enantiomers and the diastereomers as well as their mixtures. They can be separated according to customary methods.

[0357] The compounds according to the invention can exist in tautomeric forms. This is known to the artisan and such compounds are also object of the present invention.

[0358] The synthesis of the compounds according to the invention (I) can be illustrated by the following scheme 1:

[0359] Starting from α-amino acid derivatives (II), the precursor is first immobilized on a resin or esterified (step a), followed by amide coupling (step b) and further derivatized as described below.

[0360] In the above scheme, PG stands for an amino protecting group that is stable under the respective reaction conditions such as 9-fluorenylmethyloxycarbonyl (Fmoc) or tert.butyloxycarbonyl (Boc) or phtalimid. These are known to the one skilled in the art and are in detail described in Greene, T., Protective Groups in Organic Synthesis, 2^(nd) ed., John Wiley, N.Y., 1991.

[0361] According to an embodiment, starting materials used in the process according to the invention for the preparation of compounds of the general formula (I) are the following carboxylic acid derivatives (II):

[0362] Compounds of general formula (II) are commercially available, known or can be prepared by customary methods starting from known α-amino acids or precursors for customary α-amino acid synthesis. For the preparation process according to the invention, the carboxyl group is in this case blocked by a conventional protective group P. Protective groups of this type are known to the person skilled in the art and are in detail described in Greene, T., Protective Groups in Organic Synthesis, 2^(nd) ed., John Wiley, N.Y., 1991. The carboxyl group is particularly preferably esterified, P being a C₁₋₆-alkyl such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, a C₃₋₇-cycloalkyl such as, for example, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, an aryl such as, for example, phenyl, benzyl, tolyl or a substituted derivative thereof. Particularly preferably, however, the preparation process according to the invention for the compounds of the general formula (I) is carried out on a solid phase in order to achieve a process implementation which is as economical as possible. In this case, the carboxyl residue can be bonded to any solid phase conventionally used for reactions of this type. According to the invention, the solid phase used is particularly preferably a polystyrene resin and in particular a commercially available Wang polystyrene resin. In the α-position to the carboxyl group, these carboxylic acid derivatives can have substituents such as described under R⁸ and R⁹, for example, hydrogen, a C₁-C₁₀-alkyl such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, a C₃-C₇-cycloalkyl such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl an aryl such as, for example, phenyl, benzyl, tolyl or a substituted derivative thereof, an optionally substituted alkenyl residue, or an optionally substituted alkinyl residue. The alkyl, alkenyl and cycloalkyl residues and the benzyl residue can be introduced by reaction of the ester of the starting compounds with the appropriate alkyl, alkenyl, cycloalkyl or benzyl halides in basic medium, if the corresponding derivatives are not commercially available. The alkinyl residue can be introduced, for example, by reaction of the bromo ester of the present starting compound with an appropriate acetylide anion. In the case of the phenyl residue the starting materials used are preferably the corresponding α-phenyl-α-aminocarboxylic acid derivatives and, if necessary, the other substituents at the α-C atom to the terminal carboxyl group are introduced via the appropriate alkyl halide.

[0363] The above reactions and their implementation are well known to the person skilled in the art and are described in detail in standard textbooks such as, for example, Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg Thieme Verlag, Stuttgart.

[0364] If the substituents themself should be substituted, e.g by R′, appropriate reactive groups should be present in the substituent to allow further functionalization. These reactive groups should be inert to the reaction conditions of the previous step. For this purpose, the substituent can also be unsaturated to allow further functionalization such as palladium catalyzed C—C-coupling reactions (e.g. Heck-reaction or Sonogashira-reaction), eventually followed by hydration (scheme 2):

[0365] In the abovementioned scheme, hal stands for a leaving group such as a halogen, tosyl, mesyl or triflate, [Pd] stands for a Palladium(0) or Palladium(II) moiety.

[0366] If the substituent R⁸ or R⁹ in the α-position to the carboxylic group carry an appropriate substituted aryl or heteroaryl unit, another method for insertion of an additional substituent are the C—C-coupling reactions according to the following scheme 3:

[0367] The starting compounds to be employed according to the above embodiment have a terminal aryl or heteroaryl unit which must carry at least one substituent L. This substituent L must be substitutable by another aryl or heteroaryl group by means of one of the known aryl-aryl coupling procedures. According to the present invention, L can be —H, —F, —Cl, —Br, —I, —SCN, —N₂+ or an organometalllic residue. Preferred organometallic residues which may be mentioned are, for example, a magnesium, copper, boron, tin, lithium or lithium cuprate residue.

[0368] If the corresponding starting compounds are not commercially available, the terminal aryl or heteroaryl unit can be connected to the appropriate carboxylic acid derivative by standard processes such as, for example, a Friedel-Crafts alkylation, Friedel-Crafts acylation or by organometallic synthesis procedures such as, for example, a palladium-assisted coupling, after which, if appropriate, further derivatization steps follow which are known to the person skilled in the art and described in detail in standard textbooks such as, for example, Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg Thieme Verlag, Stuttgart.

[0369] In preferred embodiments according to the invention, the biphenyl nucleus is generated by means of an aryl-aryl coupling. Formally, in this case the residue L at the terminal aryl or heteroaryl group of the carboxylic acid derivative serving as a starting compound is replaced by a aryl or heteroaryl compound of the following formula:

[0370] Possible coupling reactions are, for example, the reaction of two unsubstituted phenyl groups (i.e. L and M are hydrogen) in the presence of AlCl₃ and an acid (Scholl reaction), the coupling of the two phenyl iodides in the presence of copper (Ullmann reaction), the reaction of the unsubstituted carboxylic acid derivative with a phenyldiazonium compound under basic conditions (Gomberg-Bachmann reaction) or coupling with participation of organometallic reagents. In this connection, the coupling of two phenyl Grignard compounds in the presence of thallium bromide, the coupling of two organoboron compounds in the presence of silver nitrate and sodium hydroxide, the reaction of a diphenyllithium cuprate in the presence of oxygen and palladium-assisted couplings of a phenyl halide with an organometallic phenyl compound deserve mention. The implementation of these reactions is described in detail in standard textbooks such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg Thieme Verlag, Stuttgart. The choice of the coupling reaction depends on the presence of possibly interfering or sensitive substituents in the reactants. For the preferred compounds according to the invention, however, it has proven particularly advantageous to generate the biphenyl nucleus by coupling of a phenyl halide with an organometallic phenyl compound in the presence of a palladium compound, for example a Pd(0), a Pd(II) or a Pd(IV) compound, and of a phosphane such as triphenylphosphane.

[0371] The phenyl halide used in this case can be the corresponding phenyl fluoride, chloride, bromide or iodide, the corresponding bromide being particularly preferred. The organometallic phenyl compound used is preferably a substance in which a metallic element such as, for example, zinc, magnesium, boron, lithium, copper, tin or another element conventionally used for this purpose is bonded directly to the aryl ring. According to the invention, organoboron compounds are particularly preferred.

[0372] Further substituents can be bonded to the aryl ring additionally to the residue R¹¹ and the metallic element.

[0373] According to a preferred embodiment of the present invention, the synthesis of the compounds according to the invention is carried out on a solid phase such as a polystyrene resin, particularly preferably a commercially available Wang polystyrene resin (step a). In this case, the resin is first swollen in a solvent such as dimethylformamide (DMF). The carboxylic acid serving as a starting compound is then bonded to the resin by standard procedures. For example, the bonding of the carboxylic acid to the resin can be carried out in the presence of a base such as pyridine and a reagent activating the carboxyl unit, such as an acid halide, for example dichlorobenzoyl chloride, in a solvent such as dimethylformamide (DMF). However, other reagents conventionally used for this purpose can also be employed. The reaction mixture is stirred at room temperature and normal pressure for at least 2 hours, preferably 12 hours, particularly preferably approximately 24 hours, the carboxylic acid being employed in an excess, preferably in a two- to three-fold excess, with respect to the loading of the solid phase.

[0374] The aryl-aryl coupling is preferably carried out according to the invention by treating the carboxylic acid bonded to the solid phase, in aqueous medium in the presence of a base such as sodium carbonate with the appropriate aryl coupling reagent of the formula (3) and a catalyst conventionally used for this purpose, for example a palladium(II) salt, preferably bis-(triphenylphosphane)-palladium(II) chloride in combination with triphenylphosphane. An approximately 3- to 8-fold, preferably an approximately 4- to 6-fold, excess of the aryl coupling agent and catalytically active amounts of the palladium compound, for example approximately 10 times lower than the amount of the carboxylic acid, is preferably employed in this case and, after stirring briefly at room temperature, for example for 5 to 10 minutes, the reaction mixture is heated for approximately 2-24 hours, preferably 6-24 hours and particularly preferably 12-24 hours, to a temperature in the range from 40 to 110° C., preferably 50 to 100° C. and particularly preferably 60 to 90° C. The biphenyl compound obtained can immediately be reacted further without purification after unreacted reactants which may be present are removed by washing with an acidic solution, for example a hydrochloric acid solution.

[0375] The functionalization of the α-amino acid moiety as described above can also take place after the formation of the amide bond. Preferred, however, is functionalization before formation of the amide bond.

[0376] According to the invention the amide coupling (step b) is carried out with carboxylic acid of general formula (III), which are commercially available, known or can be prepared by customary methods starting from known B-amino acids or precursors for customary B-amino acid synthesis.

[0377] For the introduction of a substituent into the β-position relative to the carboxyl group, the possibility that suggests itself, for example, is to start from the corresponding α,β-unsaturated carboxylic acid derivatives and to react these with the respective alkyl or cycloalkyl cuprates in the sense of a Michael addition. β-substituted derivatives are also accessible via the condensation of a derivative of malonic acid with an aldehyde or a keton or by C₁ chain elongation by Arndt-Eistert reaction. Subsequently, if desired, another substituent can be introduced into the α-position relative to the carboxyl group. These substituents in α-position can be introduced essentially according to the same methods as described for the compounds of formula (II), with the exception that β-amino acid derivatives are used instead of α-amino acids.

[0378] These reactions and their implementation are also well known to the person skilled in the art and are described in detail in standard textbooks such as, for example, Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg Thieme Verlag, Stuttgart.

[0379] In one preferred embodiment, introduction of a substituent into the β-position relative to the carboxyl group takes place before introduction of a substituent into the α-position relative to the carboxyl group

[0380] The α-amino acids used according to the invention are commercially available, for example, from Novabiochem or Bachem. The β-amino acids can in some cases likewise be obtained from these companies or can be prepared according to the procedures of T. B. Johnson, Journal of the American Chemical Society, 1936, 58, or of V. A. Soloshonok, Tetrahedron Assymetry, 1995, 1601. These amino acids can be converted into the desired carboxyl-protected amino acid derivative, for example, by protection of the amino group, optionally subsequent protection of the carboxylic acid unit and subsequent deprotection of the amino group. Protective groups which can be used in this case for the amino group are all groups known for this purpose. According to the invention, the use of a 9-fluorenylmethoxycarbonyl group (FMOC) as a protective group for the amino unit is particularly preferred. The carboxylic acid group is optionally protected or derivatized as described above.

[0381] For the preparation of precursors (IV) (Step b), (II) is deprotected and coupled with (III) in an amide formation reaction. The reaction conditions and coupling agents as well as the deprotection conditions are well known to the one skilled in the art and described in Y. Angell et al. Tetrahedron Letters, 35, 1994, 5981-4.

[0382] According to a preffered embodiment, to a solution of β-amino acid derivatives of general formula (III) in dimethylformamide O-(7-azabenzotriazol-1-yl)1,1,3,3-tetramethyluronium hexafluorophosphate and diisopropylethylamin were added. After shaking the mixture for about 15 minutes, the deprotected compounds of general formula (II) (optionally immobilized on resin) were treated with this solution for about 4 hours at medium temperature, e.g. room temperature. The workup follows standard procedure known to the person skilled in the art, e.g. the derivatized resin (IV) is washed with dimethylformamide and tetrahydrofurane.

[0383] The deprotected amino function of compounds (IV) can be functionalized by a variety of acceptor substituents (step d) such as carbonyl-, aminocarbonyl-, oxycarbonyl-, sulfonyl-, oxalyl-, pyrimidyl- and pyridyl-derivatives.

[0384] This formation of the respective e.g. amide-, urea-, carbamate-, sulfonamide-moieties is known to the person skilled in the art and in detail described in Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg Thieme Verlag, Stuttgart.

[0385] For example, formation of the amides can take place using the respecive acid chloride or acid with a coupling agent such as DCC (Dicyclohexylcarbodiimid) or HOBT (N-Hydroxybenzotriazole) formation of the ureas can take place using the respective isocyanates, carbamates are formed using chloroformates and sulfonamides are formed using sulfonylchlorides.

[0386] For this purpose the compound (IV) is deprotected with a base, e.g. piperidine solution in dimethylformamide and shaken at room temperature for about 10 minutes and worked up. In case solid phase synthesis is used, the resin is then washed with dimethylformamide and further base solution in dimethylformamide is added. After shaking for about 20 minutes, it is washed, e.g. with dimethylformamide and tetrahydrofurane.

[0387] For example, the deprotected compound (IV) is then treated with a solution of base, e.g. diisopropylethylamine in tetrahydrofurane and a solution of acylating/sulfonylating/carbamoylating reagent, e.g. acid chloride, sulfonyl chloride or chloroformate in tetrahydrofurane. It is shaken overnight at room temperature. The derivatized compound (Va) is then worked up following standard procedure, e.g. in case solid phase synthesis is used, the resin is washed with dimethylformamide, methanol, tetrahydrofurane and dichloromethane.

[0388] In another embodiment, the deprotected compound (IV) is treated with a solution of base, e.g. diisopropylethylamine in dimethylformamide and a solution of halogen-heterocycle reagent in dimethylformamide. It is shaken for about 5-16 hours at room or elevated temperature. The derivatized compound (Vb or Vc) is then worked up according to standard procedure, e.g. in case of solid phase synthesis washed with dimethylformamide.

[0389] In case the halogen-heterocycle reagent bears further functionalizable substituents, e.g. halogen, these positions can be derivatized subsequently (step e). For example, an amine reagent in dimethylformamide is added to the derivatized compound (Vb) and the mixture is shaken overnight at room or elevated temperature. The derivatized compound is then worked up according to standard procedure, e.g. in case of solid phase synthesis washed with dimethylformamide, tetrahydrofurane, dichloromethane.

[0390] The ester derivatives according to the invention can be converted into the corresponding free carboxylic acids in a conventional manner, such as, for example, by basic ester hydrolysis (step f).

[0391] In a preferred embodiment, the immobilized compounds are subsequently released from the resin by treatment with appropriate cleavage agents, such as strong acids like trifluoroacetic acid in dichloromethane.

EXAMPLES

[0392] In the examples below, all quantitative data, if not stated otherwise, relate to percentages by weight.

[0393] For synthetic process the compounds are immobilized on solid phase. A preferred polymeric resin for this purpose is Wang polystyrene resin (Rapp-Polymere, Tübingen). As known to the one skilled in the art, the compounds can also be prepared by liquid synthetic methods using essentially the same reagents. In this case Wang polystyrene resin is substituted by an protection group for carboxyl groups such as esters.

[0394] All retention times are indicated in minutes and, if not stated otherwise, were determined by high-performance liquid chromatography (HPLC) on an RP column (Eurospher 100, C₁₈, ID 4 mm) by means of UV absorption at 214 nm. An acetonitrile/water mixture with 0,1% trifluoroacidic acid was used as eluent with following method: 0 min. =10% acteonitrile, 13 min. =80% acteonitrile, 15 min. =80% acetonitrile, 17 min. =10% acteonitrile.

[0395] The mass determinations were carried out by high-performance liquid chromatography (HPLC-MS), if not stated otherwise, using the electron spray ionization (ESI) method.

Example 1

[0396]

Example 1.1

[0397] (2S)-3-(2′,5′-dichloro[1,1′-biphenyl]-4-yl)-2-({[1-(2-methoxybenzoyl)-3-piperidinyl]-carbonyl} amino)propanoic acid

[0398] Step a

[0399] 1.2 g of Wang polystyrene resin (Rapp-Polymere, Tübingen; loading 0.96 mmol/g) are swollen in dimethylformamide. The solvent is filtered off with suction and a solution of 957 mg of (2S)-3-(4-bromophenyl)-2-(9-fluorenylmethoxycarbonyl-amino)-propionic acid in 8 ml dimethylformamide is added. After shaking at room temperature for 15 minutes, the suspension is treated with 304 PI of pyridine and 478 mg of 2,6-dichlorobenzoyl chloride. It is shaken overnight at room temperature.

[0400] The derivatized resin is then washed with dimethylformamide, methanol and dichloromethane. The resin is treated with 15 ml of a 20% strength piperidine solution in dimethylformamide and shaken at room temperature for 10 minutes. It is then washed 3 times with dimethylformamide and further 15 ml of a 20% strength piperidine solution in dimethylformamide are added. After shaking for 20 minutes, it is washed with dimethylformamide and tetrahydrofurane.

[0401] Step b

[0402] To a solution of 1.188 g of (3R,S)-N-(9-Fluorenylmethoxycarbonyl)-piperidin-3-carboxylic acid (amino acid reagent) in 7 ml dimethylformamide 1.331 g O-(7-azabenzotriazol-1-yl)1,1,3,3-tetramethyluronium hexafluorophosphate and 616 μl diisopropylethylamin were added. After shaking the mixture for 15 minutes, the derivatized resin was treated with this solution for 4 hours at room temperature. The derivatized resin is then washed with dimethylformamide and tetrahydrofurane.

[0403] Step c

[0404] The derivatized resin is suspended in 7 ml of xylene, treated with with 1.414 g of 2,5-dichlorobenzeneboronic acid (boronic acid reagent) and a solution of 1.571 g sodium carbonate in 7 ml of water and shaken for 5 minutes at room temperature. 217 mg of bis-(triphenylphosphane)-palladium(II) chloride and 162 mg of triphenylphosphane are then added and the mixture is stirred overnight at 85° C. The resin is then washed with tetrahydrofurane/water 1:1, 0.25 M aqueous hydrochloric acid, water, dimethylformamide, methanol, tetrahydrofurane and dichloromethane.

[0405] Step d

[0406] The derivatized resin is treated with 15 ml of a 20% strength piperidine solution in dimethylformamide and shaken at room temperature for 10 minutes. It is then washed 3 times with dimethylformamide and further 15 ml of a 20% strength piperidine solution in dimethylformamide are added. After shaking for 20 minutes, it is washed with dimethylformamide and tetrahydrofurane. The derivatized resin is treated with a solution of 1.6 ml of diisopropylethylamine in 12 ml tetrahydrofurane and a solution of 1.361 g of 2-methoxybenzoylchloride (acylating/sulfonylating/carbamoylating reagent) in 12 ml tetrahydrofurane. It is shaken overnight at room temperature. The derivatized resin is then washed with dimethylformamide, methanol, tetrahydrofurane and dichloromethane.

[0407] Step f

[0408] For removal of the product, the derivatized resin is shaken with 10 ml of trifluoroacetic acid/dichloromethane 1:1 for 1 hour, filtered off. The filtrate is concentrated in vacuo. 98 mg of the title compound are obtained.

[0409] Mass spectrometry (ESI): 556

[0410] Retention time (HPLC): 9.9+10.4

Example 1.2

[0411] (2S)-2-({[1-(2-chlorobenzoyl)-3-piperidinyl]carbonyl} amino)-3-(4′-methyl[1,1′-biphenyl]-4-yl)propanoic acid

[0412] (2S)-3-(4′-Methyl-biphenyl-4-yl)-2-[(2-chloro-phenylcarbonyl)-(3R,S)-piperidin-3-yl-carbonylamino]-propionic acid is prepared according to the procedure of example 1.1, with the exception that 4-methyl-benzeneboronic acid is used as boronic acid reagent instead of 2,5-dichlorobenzeneboronic acid and 2-chlorobenzoylchloride is used as acylating reagent instead of 2-methoxybenzoylchloride.

[0413] Mass spectrometry (ESI): 506

[0414] Retention time (HPLC): 9.8+10.3

Example 1.3

[0415] (2S)-2-[({1-[(2,6-dichlorophenyl)sulfonyl]-3-piperidinyl} carbonyl)amino]-3-(2′-methyl[1,1′-biphenyl]-4-yl)propanoic acid

[0416] (2S)-3-(2′-Methyl-biphenyl-4-yl)-2-[(2,6-dichloro-phenylsulfonyl)-(3R,S)-piperidin-3-yl-carbonylamino]-propionic acid is prepared according to the procedure of example 1.1, with the exception that 2-methyl-benzeneboronic acid is used as boronic acid reagent instead of 2,5-dichlorobenzeneboronic acid and 2,6-dichlorobenzenesulfonylchloride is used as acylating reagent instead of 2-methoxybenzoylchloride.

[0417] Mass spectrometry (ESI): 576

[0418] Retention time (HPLC): 11.9+12.2

[0419]¹H-NMR (400 MHz, CDCl₃) (diastereomer A=H; diastereomer B=H′) δ=7.47-7.13 (m, 11H+11H′, aryl-H+aryl-H′), 6.55 (d, 1H, NH), 6.32 (d, 1H′, NH)4.95 (dd, 1H, H-2), 4.89 (dd, 1H′, H′-2), 3.92-3.75 (m, 2H+2H′, NC-Ha+NC—H′a+NC-Hb+NC—H′b), 3.33 (dd, 1H, H-3a), 3.30 (dd, 1H′, H′-3a), 3.13 (dd, 1H, H-3b), 3.10 (m, 1H, COC—H), 3.05 (dd, 1H′, H′-3b), 2.93 (m, 1H+2H′, COC—H′+NC-Hc+NC—H′c), 2.52 (m, 1H+1H′, NC-Hd+NC—H′d), 2.24 (s, 3H, aryl-CH₃), 2.21 (s, 3H′, aryl-CH₃), 1.95-1.57 (m, 4H+4H′, 2xCH₂+2xCH′₂).

Example 1.4

[0420] (2S)-2-({I[1-(2-chlorobenzoyl)-3-piperidinyl]carbonyl}amino)-3-(2′,4′-dichloro[1,1′-biphenyl]-4-yl)propanoic acid

[0421] (2S)-3-(2′,4′-Dichloro-biphenyl-4-yl)-2-[(2-chloro-phenylcarbonyl)-(3R,S)-piperidin-3-yl-carbonylamino]-propionic acid is prepared according to the procedure of example 1.1, with the exception that 2,4-dichlorobenzeneboronic acid is used as boronic acid reagent instead of 2,5-dichlorobenzeneboronic acid and 2-chlorobenzoyichloride is used as acylating reagent instead of 2-methoxybenzoylchloride.

[0422] Mass spectrometry (ESI): 560

[0423] Retention time (HPLC): 11.6+12.3

Example 1.5

[0424] (2S)-2-[({1-[(cyclopentyloxy)carbonyl]-3-piperidinyl} carbonyl)amino]-3-(2′,5′-dichloro[1,1′-biphenyl]-4-yl)propanoic acid

[0425] (2S)-3-(2′,5′-Dichloro-biphenyl-4-yl)-2-[(cyclopentyloxycarbonyl)-(3R,S)-piperidin-3-yl-carbonylamino]-propionic acid is prepared according to the procedure of example 1.1, with the exception that cyclopentyl chloroformate is used as acylating reagent instead of 2-methoxybenzoylchloride.

[0426] Mass spectrometry (ESI): 534

[0427] Retention time (HPLC): 11.4+11.8

[0428]¹H-NMR (400 MHz, CDCl₃) (diastereomer A=H, diastereomer B=H′) δ=7.40-7.15 (m, 7H+7H′, aryl-H+aryl-H′), 5.10 (m, 1H+1H′, O—CH+O—CH′), 4.91 (dd, 1H, H-2), 4.86 (dd, 1H′, H′-2), 4.08 (m, 1H+1H′, NCHa+NCH′a), 3.96 (m, 1H+1H′, NCHb+NCH′b), 3.34 (dd, 1H, H-3a), 3.26 (dd, 1H′, H′-3a), 3.13 (dd, 1H, H-3b), 3.08 (m, 1H′, H′-3b), 2.73 (m, 2H+2H′, NCHc+NCHd+NCH′c+NCH′d), 2.45 (m, 1H, COCH), 2.33 (m, 1H′, COCH′), 1.91-1.55 (m, 12H+12H′, 6xCH₂+6xCH′₂).

Example 1.6

[0429] (2S)-2-({[1-(benzylsulfonyl)-3-piperidinyl]carbonyl}amino)-3-(2′,5′-dichloro[1,1′-biphenyl]-4-yl)propanoic acid

[0430] (2S)-3-(2′,5′-Dichloro-biphenyl-4-yl)-2-[(benylsulfonyl)-(3R,S)-piperidin-3-yl-carbonylamino]-propionic acid is prepared according to the procedure of example 1.1, with the exception that benzylsulfonylchloride is used as acylating reagent instead of 2-methoxybenzoylchloride.

[0431] Mass spectrometry (ESI): 576

[0432] Retention time (HPLC): 9.2+9.6

[0433] According to the procedure of example 1.1 following compounds shown in table 1 were prepared with the exception that optionally different boronic acids were used as boronic acid reagent instead of 2,5-dichlorobenzeneboronic acid and optionally different acid chlorides were used as acylating reagent instead of 2-methoxybenzoyl-chloride.

[0434] According to the procedure of example 1.1 the following compounds shown in table 1 were prepared with the exception that optionally different boronic acids were used as boronic acid reagent instead of 2,5-dichlorobenzeneboronic acid and optionally different sulfonylchlorides were used as sulfonylating reagent instead of 2-methoxybenzoylchloride. TABLE I structure MW MS-ESI Rt (HPLC) [min] example

470.57 471 10.2 + 10.5 1.7

490.98 491 10.5 + 10.9 1.8

470.57 470 10.3 + 10.7 1.9

500.55 501  9.5 + 10.1 1.10

462.59 463 10.9 + 11.1 1.11

553.48 554 11.9 + 12.2 1.12

490.98 491 10.1 + 10.6 1.13

486.57 487  9.6 + 10.1 1.14

514.62 515 12.3 + 12.7 1.15

464.56 465 11.3 + 11.6 1.16

484.59 485 10.9 + 11.2 1.17

505.01 506 11.3 + 11.7 1.18

484.59 485 10.9 + 11.5 1.19

514.58 515 10.3 + 10.8 1.20

476.61 477 11.7 + 11.9 1.21

567.51 568 12.5 + 12.8 1.22

528.65 529 13.0 + 13.3 1.23

492.61 493 10.7 + 11.0 1.24

583.51 584 11.6 + 12.0 1.25

521.01 522 10.0 + 10.5 1.26

516.59 517  9.5 + 10.0 1.27

544.64 545 12.1 + 12.5 1.28

494.58 495 11.1 + 11.4 1.29

484.59 485 10.7 + 10.9 1.30

505.01 506 11.0 + 11.4 1.31

484.59 485 10.8 + 11.3 1.32

514.58 515 10.0 + 10.3 1.33

476.61 477 11.4 + 11.6 1.34

567.51 568 12.4 + 12.6 1.35

505.01 506 10.6 + 11.1 1.36

500.59 501 10.1 + 10.7 1.37

528.65 529 12.8 + 13.1 1.38

478.59 479 11.8 + 12.1 1.39

539.46 540 11.8 + 12.1 1.40

559.87 560 12.1 + 12.5 1.41

539.46 540 11.9 + 12.4 1.42

569.44 570 11.0 + 11.7 1.43

531.48 532 12.6 + 12.8 1.44

622.37 623 13.3 + 13.6 1.45

555.46 556 11.2 + 11.8 1.46

583.51 584 13.7 + 14.1 1.47

533.45 534 13.0 + 13.2 1.48

539.46 540 11.5 + 11.8 1.49

559.87 560 11.8 + 12.2 1.50

539.46 540 11.6 + 12.1 1.51

569.44 570 10.7 + 11.4 1.52

531.48 532 12.3 + 12.5 1.53

559.87 560 11.4 + 12.0 1.54

566.72 567 11.1 + 11.3 1.55

506.62 507 11.2 + 11.5 1.56

550.63 551 10.5 + 10.8 1.57

542.65 543 11.9 + 12.1 1.58

561.48 562 11.4 + 11.7 1.59

552.64 553 10.3 + 10.6 1.60

560.59 561 11.4 + 11.6 1.61

557.06 558 11.4 + 11.6 1.62

506.62 507 10.7 + 10.9 1.63

561.48 562 12.5 1.64

580.74 581 11.8 + 12.0 1.65

520.65 521 11.9 + 12.1 1.66

564.66 565 11.1 + 11.4 1.67

556.68 557 12.5 + 12.7 1.68

575.51 576 12.1 + 12.3 1.69

566.67 567 11.0 + 11.3 1.70

574.62 575 12.0 + 12.2 1.71

571.09 572 11.3 + 11.6 1.72

520.65 521 12.0 + 12.3 1.73

575.51 576 13.2 1.74

596.74 597 11.0 + 11.2 1.75

536.65 537 11.0 + 11.3 1.76

580.65 581 10.4 + 10.7 1.77

572.68 573 11.7 + 12.0 1.78

591.51 592 11.3 + 11.6 1.79

590.62 591 11.2 + 11.5 1.80

587.09 588 11.3 + 11.5 1.81

536.65 537 10.5 + 10.8 1.82

591.51 592 12.3 + 12.5 1.83

580.74 581 11.6 + 11.8 1.84

520.65 521 11.7 + 11.9 1.85

564.66 565 11.0 + 11.3 1.86

556.68 557 12.4 + 12.5 1.87

566.67 567 10.9 + 11.1 1.88

574.62 575 11.8 + 12.1 1.89

571.09 572 11.8 + 12.1 1.90

520.65 521 11.1 + 11.4 1.91

575.51 576 13.0 1.92

635.61 636 12.6 + 12.8 1.93

575.51 576 12.7 + 12.9 1.94

619.52 620 11.9 + 12.2 1.95

611.54 612 13.2 + 13.5 1.96

630.37 631 12.8 + 13.1 1.97

621.54 622  9.6 1.98

629.48 630 10.7 1.99

625.95 626 10.9 1.100

575.51 576 10.0 1.101

630.37 631 11.9 1.102

635.61 636 10.3 1.103

575.51 576 10.4 1.104

619.52 620  9.3 1.105

611.54 612 11.0 1.106

630.37 631 10.6 1.107

621.54 622 8.8 + 9.2 1.108

629.48 630 10.3 1.109

625.95 626 10.0 + 10.5 1.110

630.37 631 11.5 1.111

Example 2

[0435]

Example 2.1

[0436] (2S)-3-(2′,5′-dichloro[1,1′-biphenyl]-4-yl)-2-{[(1-{5-fluoro-6-[(2-pyridinylmethyl)-amino]-4-pyrimidinyl}-3-piperidinyl)carbonyl]amino}propanoic acid

[0437] Step a

[0438] 1.2 g of Wang polystyrene resin (Rapp-Polymere, Tübingen; loading 0.96 mmol/g) are swollen in dimethylformamide. The solvent is filtered off with suction and a solution of 957 mg of (2S)-3-(4-bromophenyl)-2-(9-fluorenylmethoxycarbonyl-amino)-propionic acid in 8 ml dimethylformamide is added. After shaking at room temperature for 15 minutes, the suspension is treated with 304 μl of pyridine and 478 mg of 2,6-dichlorobenzoyl chloride. It is shaken overnight at room temperature. The derivatized resin is then washed with dimethylformamide, methanol and dichloromethane. The derivatized resin is treated with 15 ml of a 20% strength piperidine solution in Dimethylformamide and shaken at room temperature for 10 minutes. It is then washed 3 times with dimethylformamide and further 15 ml of a 20% strength piperidine solution in dimethylformamide are added. After shaking for 20 minutes, it is washed with dimethylformamide and tetrahydrofurane.

[0439] Step b

[0440] To a solution of 1.188 g of (3R,S)—N-(9-Fluorenylnethoxycarbonyl)-piperidin-3-carboxylic acid (amino acid reagent) in 7 ml dimethylformamide 1.331 g O-(7-azabenzotriazol-1-yl)1,1,3,3-tetramethyluronium hexafluorophosphate and 616 II diisopropylethylamine were added. After shaking the mixture for 15 minutes, the derivatized resin was treated with this solution for 4 hours at room temperature. The derivatized resin is then washed with dimethylformamide and tetrahydrofurane.

[0441] Step c

[0442] The derivatized resin is suspended in 7 ml of xylene, treated with with 1.414 g of 2,5-dichlorobenzeneboronic acid (boronic acid reagent) and a solution of 1.571 g sodium carbonate in 7 ml of water and shaken for 5 minutes at room temperature. 217 mg of bis-(triphenylphosphane)-palladium(II) chloride and 162 mg of triphenylphosphane are then added and the mixture is stirred overnight at 85° C. The derivatized resin is then washed with tetrahydrofurane/water 1:1, 0.25 M aqueous hydrochloric acid, water, dimethylformamide, methanol, tetrahydrofurane and dichloromethane.

[0443] Step d

[0444] The derivatized resin is treated with 15 ml of a 20% strength piperidine solution in dimethylformamide and shaken at room temperature for 10 minutes. It is then washed 3 times with dimethylformamide and further 15 ml of a 20% strength piperidine solution in dimethylformamide are added. After shaking for 20 minutes, it is washed with dimethylformamide and tetrahydrofurane. The derivatized resin is treated with a solution of 400 μl of diisopropylethylamine in 12 ml dimethylformamide and a solution of 1.223 g of 4,5,6-trifluoropyrimidine in 12 ml dimethylformamide. It is shaken for 5 hours at room temperature. The derivatized resin is then washed with dimethylformamide.

[0445] Step e

[0446] 986 mg of pyridin-2-yl-methylamine (amine reagent) in 12 ml dimethylformamide were added to the derivatized resin and the mixture is shaken overnight at room temperature. The derivatized resin is then washed with dimethylformamide, tetrahydrofurane, dichloromethane.

[0447] For removal of the product, the derivatized resin is shaken with 10 ml of trifluoroacetic acid/dichloromethane 1:1 for 1 hour, filtered off. The filtrate is concentrated in vacuo. 102 mg of the title compound are obtained.

[0448] Mass spectrometry (ESI): 624

[0449] Retention time (HPLC):

[0450]¹H-NMR (400 MHz, CDCl₃) (diastereomer A=H, diastereomer B=H′) δ=8.68-8.48 (2×d, 1H+1H′, pyridinyl-H+pyridinyl-H′), 8.32 (m, 1H+1H′, pyridinyl-H+pyridinyl-H′), 8.22 (s, 1H, pyrimidinyl-H), 8.02 (m, 1H+1H′, pyridinyl-H+pyridinyl-H′), 8.01 (s, 1H′, pyrimidinyl-H′), 7.76 (m, 1H+1H′, pyridinyl-H+pyridinyl-H′), 7.43-7.21 (m, 7H+7H′, aryl-H+aryl-H′), 5.10 (m, 2H, pyridinyl-CH₂), 5.06 (m, 2H, pyridinyl-CH₂), 4.80 (m, 1H+1H′, H-2+H′-2), 3.92 (m, 2H+2H′, NCHa+NCH′a+NCHb+NCH′b), 3.72 (m, 1H, NCHc), 3.63 (m, 1H′, NCH′c), 3.44 (m, 1H, NCHd), 3.33 (dd, 1H, H-3a), 3.30 (m, 1H′, NCH′d), 3.25 (dd, 1H′, H′-3a), 3.04 (dd, 1H, H-3b), 3.02 (dd, 1H′, H′3-b), 2.58 (m, 1H+1H′, COCH+COCH′), 1.90-1.75 (m, 4H+4H′, 2xCH₂+2xCH′₂).

Example 2.2

[0451] (2S)-3-(2′,5′-dichloro[1,1′-biphenyl]-4-yl)-2-[({1-[5-fluoro-6-(1piperazinyl)-4-pyrimidinyl]-3-piperidinyl}carbonyl)amino]propanoic acid

[0452] (2S)-3-(2′,5′-dichloro[1,1′-biphenyl]-4-yl)-2-[({1-[5-fluoro-6-(1-piperazinyl)-4-pyrimidinyl]-3-piperidinyl}carbonyl)amino]propanoic acid is prepared according to the procedure of example 2.1, with the exception that piperazine is used as amine reagent instead pyridin-2-yl-methylamine.

[0453] Mass spectrometry (ESI): 602

[0454] Retention time (HPLC): 8.0+8.4

Example 2.3

[0455] (2S)-3-(2′,5′-dichloro[1,1′-biphenyl]-4-yl)-2-[({1-[5-fluoro-6-(4-morpholinyl)-4-pyrimidinyl]-3-piperidinyl}carbonyl)amino]propanoic acid

[0456] (2S)-3-(2′,5′-dichloro[1,1′-biphenyl]-4-yl)-2-[({1-[5-fluoro-6-(4-morpholinyl)-4-pyrimidinyl]-3-piperidinyl}carbonyl)amino]propanoic acid is prepared according to the procedure of example 1.1, with the exception that morpholine is used as amine reagent instead of pyridin-2-yl-methylamine.

[0457] Mass spectrometry (ESI): 603

[0458] Retention time (HPLC): 9.4+9.6

[0459] According to the procedure of example 2.1 following compounds shown in table 2 were prepared with the exception that optionally different boronic acids were used as boronic acid reagent instead of 2,5-dichlorobenzeneboronic acid and optionally different amines were used as amine reagent instead of pyridin-2-yl-methylamine. TABLE 2 structure MW MS-ESI Rt (HPLC) [min] example

568.65 569 7.6 + 7.8 2.4

559.68 560  9.8 + 10.1 2.5

545.66 546  9.6 + 10.1 2.6

547.63 548 9.0 2.7

581.69 582 10.4 + 10.5 2.8

546.64 547 7.4 + 7.7 2.9

519.62 520 8.9 2.10

593.70 594 10.1 + 10.5 2.11

574.70 575 7.7 2.12

547.67 548 10.1 2.13

584.65 585 7.2 2.14

575.68 576 9.1 2.15

561.65 562 9.1 2.16

563.63 564 8.3 2.17

597.69 598 9.7 2.18

562.64 563 6.9 2.19

535.62 536 8.2 2.20

609.70 610 9.8 2.21

590.70 591 7.1 2.22

563.67 564 9.5 2.23

568.65 569 7.3 2.24

559.68 560 9.6 2.25

545.66 546 9.4 2.26

547.63 548 8.8 2.27

581.69 582 10.2 + 10.4 2.28

546.64 547 6.8 + 7.3 2.29

519.62 520 8.4 + 8.7 2.30

593.70 594 9.8 2.31

574.70 575 7.2 2.32

547.67 548 9.6 2.33

614.55 615 10.3 + 10.6 2.34

600.52 601 10.3 2.35

636.55 637 10.9 + 11.0 2.36

574.48 575 9.4 + 9.6 2.37

648.56 649 10.6 + 10.8 2.38

629.56 630 7.9 + 8.5 2.39

602.53 603 10.5 + 10.6 2.40

623.51 624 8.4 + 8.9 2.41

614.55 615 10.4 + 10.7 2.42

600.52 601 10.5 + 10.9 2.43

602.49 603 9.9 2.44

636.55 637 10.7 + 11.1 2.45

601.51 602 7.9 + 8.5 2.46

574.48 575  9.4 + 10.1 2.47

648.56 649 10.7 + 11.1 2.48

629.56 630 8.3 2.49

602.53 603 10.8 + 11.2 2.50

584.65 585 7.0 + 7.6 2.51

561.65 562 8.9 + 9.5 2.52

563.63 564 8.3 + 8.5 2.53

562.64 563 6.5 + 6.9 2.54

535.62 536 8.0 + 8.6 2.55

609.70 610 9.5 + 9.7 2.56

Example 3

[0460]

[0461] In the abovementioned scheme, hal stands for a leaving group such as a halogen, tosyl, mesyl or triflate.

Example 3.1

[0462] (2S)-3-(2′,5′-dichloro[1,1′-biphenyl]-4-yl)-2-({([1-(2-pyrinidinyl)-3-piperidinyl]-carbonyl} amino)propanoic acid

[0463] Step a 1.2 g of Wang polystyrene resin (Rapp-Polymere, Tübingen; loading 0.96 mmol/g) are swollen in dimethylformamide. The solvent is filtered off with suction and a solution of 957 mg of (2S)-3-(4-bromophenyl)-2-(9-fluorenylmethoxycarbonyl-amino)-propionic acid in 8 ml dimethylformamide is added. After shaking at room temperature for 15 minutes, the suspension is treated with 304 μl of pyridine and 478 mg of 2,6-dichlorobenzoyl chloride. It is shaken overnight at room temperature. The resin is then washed with dimethylformamide, methanol and dichloromethane. The resin is treated with 15 ml of a 20% strength piperidine solution in Dimethylformamide and shaken at room temperature for 10 minutes. It is then washed 3 times with dimethylformamide and further 15 ml of a 20% strength piperidine solution in dimethylformamide are added. After shaking for 20 minutes, it is washed with dimethylformamide and tetrahydrofurane.

[0464] Step b

[0465] To a solution of 1.188 g of (3R,S)—N-(9-Fluorenylmethoxycarbonyl)-piperidin-3-carboxylic acid (amino acid reagent) in 7 ml dimethylformamide 1.331 g O-(7-azabenzotriazol-1-yl) 1,1,3,3-tetramethyluronium hexafluorophosphate and 616 μl diisopropylethylamine were added. After shaking the mixture for 15 minutes, the resin was treated with this solution for 4 hours at room temperature. The resin is then washed with dimethylformamide and tetrahydrofurane.

[0466] Step c

[0467] The resin is suspended in 7 ml of xylene, treated with with 1.414 g of 2,5-dichlorobenzeneboronic acid (boronic acid reagent) and a solution of 1.571 g sodium carbonate in 7 ml of water and shaken for 5 minutes at room temperature. 217 mg of bis-(triphenylphosphane)-palladium(II) chloride and 162 mg of triphenylphosphane are then added and the mixture is stirred overnight at 85° C. The resin is then washed with tetrahydrofurane/water 1:1, 0.25 M aqueous hydrochloric acid, water, dimethylformamide, methanol, tetrahydrofurane and dichloromethane.

[0468] Step d

[0469] The resin is treated with 15 ml of a 20% strength piperidine solution in dimethylformamide and shaken at room temperature for 10 minutes. It is then washed 3 times with dimethylformamide and further 15 ml of a 20% strength piperidine solution in dimethylformamide are added. After shaking for 20 minutes, it is washed with dimethylformamide and tetrahydrofurane. The resin is treated with a solution of 600 μl of diisopropylethylamine in 6 ml dimethylformamide and a solution of 1.956 g 2-chloropyrimidine (halogen-heterocycle reagent) in 6 ml dimethylformamide. It is shaken overnight at 85° C. (reaction conditions). The resin is then washed with dimethylformamide, methanol, tetrahydrofurane, dichloromethane.

[0470] Step f

[0471] For removal of the product, the resin is shaken with 10 ml of trifluoroacetic acid/dichloromethane 1:1 for 1 hour, filtered off. The filtrate is concentrated. 98 mg of the title compound are obtained.

[0472] Mass spectrometry (ESI): 500

[0473] Retention time (HPLC): 9.9

Example 3.2

[0474] (2S)-2-({[1-(1H-benzimidazol-2-yl)-3-piperidinyl] carbonyl} amino)-3-(2′,5′-dichloro-[1,1′-biphenyl]-4-yl)propanoic acid

[0475] (2S)-2-({[1-(1H-benzimidazol-2-yl)-3-piperidinyl]carbonyl} amino)-3-(2′,5′-dichloro-[1,1′-biphenyl]-4-yl)propanoic acid is prepared according to the procedure of example 3.1, with the exception that 2-chloro-1H-benzimidazole is used as halogen-heterocycle reagent instead of 2-chloropyrimidine at 105° C. overnight (reaction conditions).

[0476] Mass spectrometry (ESI): 538

[0477] Retention time (HPLC): 8.8+8.9

Example 3.3

[0478] (2S)-3-(2′,5′-dichloro[1,1′-biphenyl]-4-yl)-2-({[1-(5-nitro-2-pyridinyl)-3-piperidinyl]-carbonyl}amino)propanoic acid

[0479] (2S)-3-(2′,5′-dichloro[1,1′-biphenyl]-4-yl)-2-({[1-(5-nitro-2-pyridinyl)-3-piperidinyl]-carbonyl}amino)propanoic acid is prepared according to the procedure of example 3.1, with the exception that 2-chloro-5-nitro-pyridine is used as halogen-heterocycle reagent instead of 2-chloropyrimidine.

[0480] Mass spectrometry (ESI): 544

[0481] Retention time (HPLC): 10.9+11.2

Example 4

[0482]

Example 4.1

[0483] N—{[1-(2-methoxybenzoyl)-3-piperidinyl]carbonyl}-4-{[(4-methyl-1-piperazinyl)-carbonyl]amino}-L-phenylalanine

[0484] Step a 1.2 g of Wang polystyrene resin (Rapp-Polymere, Tübingen; loading 0.96 mmol/g) are swollen in dimethylformamide. The solvent is filtered off with suction and a solution of 920 mg of 4-nitro-L-phenylalanine in 8 ml dimethylformamide is added.

[0485] After shaking at room temperature for 15 minutes, the suspension is treated with 304 ill of pyridine and 478 mg of 2,6-dichlorobenzoyl chloride. It is shaken overnight at room temperature. The resin is then washed with dimethylformamide, methanol and dichloromethane.

[0486] Step b

[0487] The resin is treated with a solution of 5.4 g of tin(II) chloride dihydrate in 12 ml of N-methylpyrrolidone and shaken overnight at room temperature. The resin is then washed with N-methylpyrrolidone, methanol, tetrahydrofuran and dichloromethane.

[0488] Step c

[0489] A solution of 577 μl diisopropylethylamine in 5 ml dichloromethane and 1,3 g 4-nitrophenylchloroformic acid ester in 5 ml tetrahydrofuran is subsequently given to the resin. After shaking at room temperature for 45 minutes, it is washed with tetrahydrofuran and N-methylpyrrolidone.

[0490] Step d

[0491] A solution of 774 mg of N-methylpiperazine (amine reagent) and 1.3 ml of diisopropylethylamine in 6 ml N-methylpyrrolidone is added to the resin. After shaking for 2 h, the resin is washed with dimethylformamide, methanol, tetrahydrofliran and dichloromethane.

[0492] Step e

[0493] A solution of 867 mg O-(7-azabenzotriazol-1-yl)1,1,3,3-tetramethyluronium hexafluorophosphate in 5.7 ml and 397 μl diisopropylethylamine were added to a solution of 801 mg of (3R,S)—N-(9-Fluorenylmethoxycarbonyl)-piperidin-3-carboxylic acid in 5.7 ml dimethylformamide. After shaking the mixture for 15 minutes, the resin was treated with this solution for 4 hours at room temperature. The resin is then washed with dimethylformamide and tetrahydrofurane.

[0494] Step f

[0495] The derivatized resin is treated with 15 ml of a 20% strength piperidine solution in dimethylformamide and shaken at room temperature for 10 minutes. It is then washed 3 times with dimethylformamide and further 15 ml of a 20% strength piperidine solution in dimethylformamide are added. After shaking for 20 minutes, it is washed with dimethylformamide and tetrahydrofurane. The derivatized resin is treated with a solution of 1.6 ml of diisopropylethylamine in 12 ml tetrahydrofurane and a solution of 1.361 g of 2-methoxybenzoylchloride (acylating/sulfonylating/carbamoylating reagent) in 12 ml tetrahydrofurane. It is shaken overnight at room temperature. The derivatized resin is then washed with dimethylformamide, methanol, tetrahydrofurane and dichloromethane.

[0496] Step g

[0497] For removal of the product, the derivatized resin is shaken with 10 ml of trifluoroacetic acid/dichloromethane 1:1 for 1 hour, filtered off. The filtrate is concentrated in vacuo and purified on silica gel. 93 mg of the title compound are obtained.

[0498] Mass spectrometry (ESI): 552

[0499] Retention time (HPLC): 4.5 TABLE 3 structure MW MS-ESI Rt (HPLC) [min] example

541.67 542 1.6 4.2

605.62 606 2.0 4.3

590.60 591 2.9 4.4

495.60 496 0.3 4.5

617.73 618 1.8 4.6

556.69 557 2.8 4.7

667.69 668 3.1 4.8

574.70 575 2.8 4.9

693.87 694 2.6 4.10

571.70 572 2.0 4.11

536.63 537 2.6 4.12

592.58 593 2.6 4.13

613.72 614 2.8 4.14

648.77 649 3.0 4.15

607.73 608 2.2 4.16

538.61 539 2.6 4.17

603.75 604 2.8 4.18

629.72 630 3.0 4.19

638.65 639 3.1 4.20

522.61 523 2.3 4.21

538.61 539 2.2 4.22

598.71 599 2.8 4.23

641.77 642 2.0 4.24

528.63 529 2.3 4.25

625.77 626 2.0 4.26

584.68 585 2.8 4.27

571.70 572 1.8 4.28

613.52 613 2.8 4.29

594.69 595 2.7 4.30

647.80 648 2.4 4.31

661.83 662 2.2 4.32

596.73 597 2.9 4.33

604.68 605 2.4 4.34

723.90 724 2.8 4.35

660.82 661 3.1 4.36

557.67 558 2.6 4.37

684.22 684 3.1 4.38

640.76 641 3.1 4.39

707.85 708 2.1 4.40

592.72 593 3.0 4.41

550.66 551 2.4 4.42

558.66 559 2.6 4.43

558.66 559 2.5 4.44

769.92 770 2.7 4.45

633.77 634 3.0 4.46

633.77 634 2.9 4.47

650.76 651 2.9 4.48

526.57 527 2.2 4.49

601.68 602 2.7 4.50

539.61 540 1.5 4.51

489.58 490 2.0 4.52

560.70 561 2.9 4.53

551.65 552 2.7 4.54

628.73 629 2.8 4.55

636.73 637 3.0 4.56

554.63 555 1.4 4.57

529.64 530 2.3 4.58

599.69 600 2.7 4.59

569.67 570 2.8 4.60

541.58 542 2.2 4.61

550.66 551 1.6 4.62

553.62 554 2.3 4.63

Example 5

[0500]

Example 5.1

[0501] N-({1-[5-fluoro-6-(4-morpholinyl)-4-pyrimidinyl]-3-piperidinyl}carbonyl)-4-{[(4-methyl-1-piperazinyl)carbonyl]amino}-L-phenylalanine

[0502] Step a

[0503] 1.2 g of Wang polystyrene resin (Rapp-Polymere, Tübingen; loading 0.96 mmol/g) are swollen in dimethylformamide. The solvent is filtered off with suction and a solution of 920 mg of 4-nitro-L-phenylalanine in 8 ml dimethylformamide is added.

[0504] After shaking at room temperature for 15 minutes, the suspension is treated with 304 μl of pyridine and 478 mg of 2,6-dichlorobenzoyl chloride. It is shaken overnight at room temperature. The resin is then washed with dimethylformamide, methanol and dichloromethane.

[0505] Step b

[0506] The resin is treated with a solution of 5.4 g of tin(II) chloride dihydrate in 12 ml of N-methylpyrrolidone and shaken overnight at room temperature. The resin is then washed with N-methylpyrrolidone, methanol, tetrahydrofuran and dichloromethane.

[0507] Step c

[0508] A solution of 577 μl diisopropylethylamine in 5 ml dichloromethane and 1,3 g 4-nitrophenylchloroformic acid ester in 5 ml tetrahydrofuran is subsequently given to the resin. After shaking at room temperature for 45 minutes, it is washed with tetrahydrofuran and N-methylpyrrolidone.

[0509] Step d

[0510] A solution of 774 mg of N-methylpiperazine (amine reagent) and 1.3 ml of diisopropylethylamine in 6 ml N-methylpyrrolidone is added to the resin. After shaking for 2 h, the resin is washed with dimethylformamide, methanol, tetrahydrofuran and dichloromethane.

[0511] Step e

[0512] A solution of 867 mg O-(7-azabenzotriazol-1-yl)1,1,3,3-tetramethyluronium hexafluorophosphate in 5.7 ml and 397 μl diisopropylethylamine were added to a solution of 801 mg of (3R,S)—N-(9-Fluorenylmethoxycarbonyl)-piperidin-3-carboxylic acid in 5.7 ml dimethylformamide. After shaking the mixture for 15 minutes, the resin was treated with this solution for 4 hours at room temperature. The resin is then washed with dimethylformamide and tetrahydrofuran.

[0513] Step f

[0514] The derivatized resin is treated with 15 ml of a 20% strength piperidine solution in dimethylformamide and shaken at room temperature for 10 minutes. It is then washed 3 times with dimethylformamide and further 15 ml of a 20% strength piperidine solution in dimethylformamide are added. After shaking for 20 minutes, it is washed with dimethylformamide and tetrahydrofuran. The derivatized resin is treated with a solution of 400 μl of diisopropylethylamine in 12 ml dimethyl-formamide and a solution of 1.223 g of 4,5,6-trifluoropyrimidine in 12 ml dimethylformamide. It is shaken for 5 hours at room temperature. The derivatized resin is then washed with dimethylformamide.

[0515] Step g

[0516] 794 mg of morpholine (amine reagent) in 12 ml dimethylformamide were added to the derivatized resin and the mixture is shaken overnight at room temperature. The derivatized resin is then washed with dimethylformamide, tetrahydrofuran, dichloromethane.

[0517] Step h

[0518] For removal of the product, the derivatized resin is shaken with 10 ml of trifluoroacetic acid/dichloromethane 1:1 for 1 hour, filtered off. The filtrate is concentrated in vacuo and purified on silica gel. 100 mg of the title compound are obtained.

[0519] Mass spectrometry (ESI): 599

[0520] Retention time (HPLC): 4.1 TABLE 4 ex- Rt (HPLC) am- structure MW MS-ESI [min]* ple

666.80 667 2.3 + 2.4 5.2

587.66 588 2.2 + 2.3 5.3

493.54 494 2.4 + 2.5 5.4

599.71 600 0.3 + 0.4 5.5

684.78 685 2.1 5.6

662.77 663 2.0 5.7

605.67 606 2.6 5.8

569.64 570 2.2 5.9

644.76 645 2.7 5.10

618.72 619 2.0 5.11

660.75 661 2.8 5.12

582.68 583 1.7 5.13

673.80 674 2.2 5.14

675.81 676 2.1 5.15

619.70 620 2.7 5.16

676.82 677 3.1 5.17

708.84 709 2.4 5.18

770.91 771 3.3 5.19

610.74 611 2.1 5.20

597.70 598 2.6 5.21

688.81 689 1.9 5.22

763.92 764 2.3 5.23

596.71 597 1.9 5.24

632.74 633 2.1 5.25

694.82 695 3.1 5.26

644.76 645 2.2 5.27

606.66 607 1.8 5.28

619.70 620 0.3 + 0.5 5.29

681.78 682 2.3 5.30

619.70 620 0.3 5.31

625.75 626 0.3 + 0.4 5.32

624.77 625 2.2 5.33

528.59 529 0.3 5.34

611.72 612 2.7 5.35

611.72 612 2.8 5.36

681.78 682 2.2 5.37

657.79 658 3.3 5.38

695.80 696 2.3 5.39

644.76 645 2.1 + 2.2 5.40

643.77 644 3.1 5.41

590.66 591 2.4 5.42

686.84 687 3.2 5.43

652.73 653 2.3 5.44

619.70 620 2.7 5.45

662.77 663 2.8 5.46

606.66 607 1.9 5.47

[0521] In Vitro Assay: Adhesion of Jurkat Cells to Immobilized VCAM-1 (Domains 1-3).

[0522] Preparation of Fluorescence Labeled Jurkat Cells:

[0523] Jurkat cells (American Type Culture Collection, Clone E6-1, ATCC TIB-152) were cultured in RPMI 1640 medium (Nikken Bio Medical Laboratory, CM1101) supplemented with 10% fetal bovine serum (Hyclone, A-1119-L), 100 U/ml penicilin (Gibco BRL, 15140-122) and 100 μg/ml streptomycin (Gibco BRL, 15140-122) in a humidified incubator at 37° C. with 5% CO₂.

[0524] Jurkat cells were incubated with phosphate balanced solution (PBS, Nissui, 05913) containing 25 μM of 5(-and −6)-carboxyfluorescein diacetate, succinimidyle ester (CFSE, Dojindo Laboratories, 345-06441) for 20 min at room temperature while gently swirling every 5 min. After centrifugation at 1000 rpm for 5 min, the cell pellet was resuspended with adhesion assay buffer at a cell density of 2×10⁶ cells/ml. The adhesion assay buffer was composed of 24 mM Tris-HCl (pH 7.4), 137 mM NaCl, 27 mM KCl, 4 mM glucose, 0.1% bovine serum albumin (BSA, Sigma, A9647) and 2 mM MnCl₂.

[0525] Preparation of VCAM-1 (Extracellular Domains 1-3):

[0526] Complementary DNA (cDNA) encoding 7-domain form of VCAM-1 (GenBank accession #M60335) was obtained using Rapid-Screen™ cDNA library panels (OriGene Technologies, Inc) at Takara Gene Analysis Center (Shiga, Japan). The primers used were 5′-CCA AGG CAG AGT ACG CAA AC-3′ (sence) and 5′-TGG CAG GTA TTA TTA AGG AG-3′ (antisense). PCR amplification of the 3-domain VCAM-1 cDNA was perform using Pfu DNA polymerase (Stratagene) with the following sets of primers: (U-VCAMd1-3) 5′-CCA TAT GGT ACC TGA TCA ATT TAA AAT CGA GAC CAC CCC AGA A-3′; (L-VCAMd1-3) 5′-CCA TAT AGC AAT CCT AGG TCC AGG GGA GAT CTC AAC AGT AAA-3′. PCR cycle was 94° C. for 45 sec, 55° C. for 45 sec, 72° C. for 2 min, repeating 15 cycles. After the purification of the PCR product, the fragment was digested with KpnI-AvrII. The digested fragment was ligated into pBluescript IISK(−) (Strategene), which was linealized by digesting with KpnI-XhoI. The ligation was followed by transformation to a Dam/Dcm methylase-free E. coli strain SCSI 110 (Strategene) to create the donor plasmid pH7. To direct VCAM-1 molecule into the insect cell secretory pathway, the VCAM-1 coding sequence was fused to signal peptide sequence of honeybee melittin. The resulting melittin-VCAM fusion was placed in correct orientation to the baculovirus polyhedrin promoter. Baculovirus transfer vector containing first 3-domain form VCAM-1 (pH10) was constructed by ligation of 0.9 kb fragment from AvrII/Klenow/BcII digests of pH7 into SalI/Kienow/BamnHI digests of pMelBacB (Invitrogen). Recombinant baculovirus was generated by using Bac-N-Blue™ Transfection kit (Invitrogen) according to the manufacture's instruction. The recombinant virus was amplified by infection to High-Five™ insect cells for 5-6 days, and virus titer was determined by plaque assay.

[0527] High-Five™ insect cells were pelleted in a 225 ml conical tube by centrifugation at 1000 rpm for 5 min. After discarding the supernatant, the pellet was resuspended in 1.5×10⁹ pfu (MOI=5) of high-titer virus solution, followed by incubation for 1.5 hours at room temperature. The cells were pelleted again and washed once in fresh Express Five™ serum free medium. The cells were pelleted again and finally, resuspended in 200 ml of fresh Express Five TM medium, transferred to a 1,000 ml shaker flask, and incubated in a shaker at 27° C., 130 rpm, for 48 hours before the culture supernatant was collected. The purification of 3-domain form of VCAM-1 from the culture supernatant was performed by one-step anion exchange chromatography. Protein concentration was determined by using Coomassie protein assay reagent (Pierce) according to the manufacture's instruction.

[0528] Preparation of Microtiter Plates:

[0529] Recombinant human VCAM-1 (extracellular domains 1-3) was dissolved at 0.5 μg/ml in PBS. Each well of the microtiter plates (Nalge Nunc International, Fluoronunc Cert, 437958) was coated with 100 μl of substrate or for background control with buffer alone for 15 hours at 4° C. After discarding the substrate solution, the wells were blocked using 150 μl per well of block solution (Kirkegaard Perry Laboratories, 50-61-01) for 90 minutes. The plate was washed with wash buffer containing 24 mM Tris-HCl (pH 7.4), 137 mM NaCl, 27 mM KCl and 2 mM MnCl₂ just before addition of the assay solution containing Jurkat cells and VLA-4 inhibitor.

[0530] Assay Procedure:

[0531] Labeled Jurkat cells were incubated for 30 min at 37° C. with each test compounds, at a concentration of 3 μM or at various concentrations ranging from 0.0001 μM to 10 μM using a standard 5-point serial dilution. The assay solution was transfered to the VCAM-1 coated plates at a cell density of 2×10⁵ cells per well and incubated for 1 hour at 37° C. The non-adherent cells were removed by washing the plates 3 times with wash buffer. The adherent cells were broken by addition of 1% Triton X-100 (Nacalai Tesque, 355-01). Released CFSC was quantified fluorescence measurement in a fluorometer (Wallac, ARVO 1420 multilabel counter).

[0532] The adhesion of Jurkat cells to VCAM-1 was analyzed by percent binding calculated by the formula:

[0533] [(FTB-FBG)−(FTS-FBG)]/(FTB-FBG)×100=% binding, where FTB is the total fluorescent intensity from VCAM-1 coated wells without test compound; FBG is the fluorescent intensity from wells lacking VCAM-1 and FTS is the fluorescent intensity from wells containing the test compound of this invention.

[0534] IC₅₀-values can then be calculated from the resulting % binding, when 100% binding relate to 100% adhesion, 0% inhibition result.

[0535] The test results were shown in tables 5 to 10 below. The data correspond to the compounds as yielded by solid phase synthesis and thus to levels of purity of about 40-90%.

[0536] For practical reasons, the compounds are grouped in four classes of activity as follows:

IC₅₀=A<0.5 μM<B<21M<C<10 μM<D TABLE 5 Example IC₅₀ 1.1 A 1.2 C-D 1.3 B 1.4 B 1.5 A 1.6 A 2.1 A 2.2 A 2.3 A

[0537] TABLE 6 example IC₅₀ 1.7 C-D 1.8 C-D 1.9 C-D 1.10 C-D 1.11 C-D 1.12 C-D 1.13 C-D 1.14 C-D 1.15 C-D 1.16 C 1.17 C-D 1.18 C-D 1.19 C-D 1.20 C-D 1.21 C-D 1.22 C-D 1.23 C-D 1.24 C-D 1.25 C-D 1.26 B 1.27 C-D 1.28 C-D 1.29 C-D 1.30 C-D 1.31 C 1.32 C 1.33 C-D 1.34 C-D 1.35 C-D 1.36 C-D 1.37 B 1.38 C-D 1.39 B 1.40 C-D 1.41 C-D 1.42 B-C 1.43 C-D 1.44 C-D 1.45 C-D 1.46 C 1.47 C-D 1.48 C 1.49 C-D 1.50 C 1.51 C-D 1.52 C-D 1.53 C-D 1.54 C

[0538] TABLE 7 example IC₅₀ 1.55 C-D 1.56 B 1.57 C-D 1.58 C-D 1.59 C-D 1.60 C-D 1.61 C-D 1.62 C-D 1.63 C-D 1.64 C-D 1.65 C-D 1.66 C-D 1.67 C-D 1.68 C-D 1.69 C-D 1.70 C-D 1.71 C-D 1.72 C-D 1.73 C-D 1.74 C-D 1.75 C-D 1.76 C-D 1.77 C-D 1.78 C-D 1.79 C-D 1.80 C-D 1.81 C-D 1.82 C-D 1.83 C-D 1.84 C-D 1.85 B 1.86 C 1.87 B 1.88 C 1.89 C-D 1.90 C-D 1.91 C-D 1.92 C-D 1.93 C-D 1.94 C-D 1.95 C-D 1.96 C-D 1.97 C 1.98 C 1.99 C-D 1.100 C-D 1.101 C-D 1.102 C-D 1.103 C-D 1.104 A 1.105 C-D 1.106 C-D 1.107 C-D 1.108 C-D 1.109 C-D 1.110 C-D 1.111 C-D

[0539] TABLE 8 example IC₅₀ 2.4 C 2.5 C-D 2.6 C-D 2.7 C-D 2.8 C-D 2.9 B-C 2.10 C-D 2.11 C-D 2.12 C-D 2.13 C-D 2.14 C-D 2.15 C-D 2.16 C-D 2.17 C-D 2.18 C-D 2.19 C-D 2.20 C-D 2.21 C-D 2.22 C-D 2.23 C-D 2.24 C-D 2.25 C-D 2.26 C-D 2.27 C-D 2.28 C-D 2.29 C-D 2.30 C 2.31 C-D 2.32 C-D 2.33 C-D 2.34 C 2.35 C-D 2.36 C-D 2.37 C-D 2.38 C-D 2.39 B 2.40 A-B 2.41 C-D 2.42 C-D 2.43 C-D 2.44 C-D 2.45 C-D 2.46 C-D 2.47 C-D 2.48 C-D 2.49 C-D 2.50 C-D 2.51 B 2.52 C-D 2.53 C 2.54 A 2.55 A 2.56 B-C

[0540] TABLE 9 example IC₅₀ 4.2 A 4.3 B 4.4 C 4.5 B 4.6 A 4.7 B 4.8 C 4.9 A 4.10 A 4.11 A 4.12 A 4.13 B 4.14 A 4.15 B 4.16 A 4.17 B 4.18 A 4.19 C 4.20 C 4.21 B 4.22 A 4.23 B 4.24 B 4.25 A 4.26 C 4.27 A 4.28 B 4.29 A 4.30 A 4.31 B 4.32 C 4.33 A 4.34 A 4.35 B 4.36 C 4.37 B 4.38 B 4.39 C 4.40 C 4.41 A 4.42 A 4.43 A 4.44 B 4.45 B 4.46 A 4.47 B 4.48 A 4.49 A 4.50 A 4.51 A 4.52 A 4.53 B 4.54 B 4.55 B 4.56 B 4.57 B 4.58 B 4.59 B 4.60 B 4.61 B 4.62 B 4.63 B

[0541] TABLE 10 example IC₅₀ 5.2 C 5.3 C 5.4 B 5.5 C 5.6 C 5.7 B 5.8 B 5.9 C 5.10 C 5.11 B 5.12 C 5.13 C 5.14 C 5.15 C 5.16 C 5.17 B 5.18 B 5.19 B 5.20 B 5.21 B 5.22 C 5.23 B 5.24 C 5.25 B 5.26 C 5.27 C 5.28 B 5.29 C 5.30 B 5.31 B 5.32 B 5.33 C 5.34 A 5.35 A 5.36 B 5.37 B 5.38 B 5.39 B 5.40 B 5.41 B 5.42 A 5.43 B 5.44 B 5.45 B 5.46 B 5.47 B 

1. A compound of formula (I),

wherein R¹, together with the carbon atom to which it is attached, and R², together with the nitrogen atom to which it is attached, form a piperidinyl ring; R³ represents hydrogen; R⁴ represents hydrogen; R⁵ represents hydrogen; R⁶ represents C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, or C₃-C₇ cycloalkyl, which can optionally be substituted by 1 to 3 radicals R³¹ and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, or C₆ or C₁₀ aryl, which can optionally be substituted by 1 to 3 radicals R³¹, wherein R³¹ represents —OR³², wherein R³² represents C₁-C₄ alkyl; R⁷ represents hydrogen; R⁸ represents hydrogen; R⁹ represents hydrogen, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-Cg heteroaryl or a heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R⁴³, and which can furthermore be single-foldedly substituted by C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, C₄-Cg heteroaryl or a heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can optionally be substituted by 1 to 3 radicals R⁴³, wherein R⁴³ represents C₁-C₄ alkyl, trifluormethyl, trifluormethoxy, —OR⁴⁴, —SR⁴⁴, NR⁴⁵R⁴⁶, C(O)R⁴⁴, S(O)R⁴⁴, —SO₂R⁴⁴, —CO₂R⁴⁴, —OC(O)R⁴⁴, —C(O)NR⁴⁵R⁴⁶, —NR⁴⁴C(O)R⁴⁴, —SO₂NR⁴⁵R⁴⁶, NR⁴⁴SO₂R⁴⁴, —NR⁴⁴C(O)NR⁴R⁴⁶, —NR⁴⁴C(O)OR⁴⁴, —OC(O)NR⁴⁵R⁴⁶, halogen, cyano, tetrazolyl, nitro or oxo, wherein R⁴⁴ represents hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₆ or C₁₀ aryl which can optionally be substituted by 1 substituent selected from the group C₁-C₄ alkyl, C₁-C₄ alkyloxy, phenyl, C₃-C₆ cycloalkyl, halogen, nitro, cyano, and wherein R⁴⁵ and R⁴⁶ are identical or different and represent hydrogen, C₁-C₁₀ alkyl, C₆ or C₁₀ aryl, C₃-C₇ cycloalkyl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can furthermore be substituted by C₁-C₁₀ alkyl, C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, benzyl, diphenylmethyl, C₄-Cg heteroaryl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, or R⁴⁵ and R⁴⁶ together form a 4-7-membered ring, which includes the nitrogen atom to which R⁴⁵ and R⁴⁶ are bonded and which contains up to 2 additional heteroatoms selected from the group oxygen, nitrogen or sulfur and which contains up to 2 double bonds, which can furthermore be substituted by C₁-C₁₀ alkyl, C₃-C₇ cycloalkyl, C₆ or C₁₀ aryl, benzyl, diphenylmethyl, C₄-Cg heteroaryl or a 4-9-membered saturated or unsaturated heterocyclic residue containing up to 2 heteroatoms selected from the group oxygen, nitrogen or sulfur, which can be fused with a 3-7 membered homocyclic or heterocyclic, saturated or unsaturated ring, A represents —SO—, or —SO_(2—); X represents a bond, oxygen or —NR¹², wherein R¹² represents hydrogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, or C₂-C₄ alkynyl; Y represents oxygen; and Z represents —C(O)OR⁴⁷, wherein R⁴⁷ represents hydrogen; or a pharmaceutically acceptable salt thereof.
 2. The compound of claim 1, wherein R⁶ represents C₁-C₁₀ alkyl, or C₁₀ aryl or C₃-C₇ cycloalkyl, which can optionally be-substituted by 1 to 3 radicals R³¹, wherein R³¹ represents —OR³² or halogen, wherein R³² represents methyl; R⁹ represents C₁-C₁₀ alkyl, which is single-foldedly substituted by C₆ aryl, which is single-foldedly substituted by C₆ aryl, which can optionally be substituted by 1 to 3 radicals R⁴³, wherein R⁴³ represents C₁-C₄ alkyl, —OR⁴⁴ or halogen, wherein R⁴⁴ represents C₁-C₄ alkyl, or a pharmaceutically acceptable salt thereof.
 3. The compound of claim 1, wherein A represents —SO₂—, or a pharmaceutically acceptable salt thereof.
 4. (canceled)
 5. (canceled)
 6. (canceled)
 7. (canceled)
 8. (canceled)
 9. (canceled)
 10. (canceled)
 11. (canceled).
 12. A method of treating a condition mediated by integrins comprising administering to a mammal an effective amount of a compound of claim
 1. 13. A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
 14. A method of treating arteriosclerosis, asthma, allergies, diabetes, inflammatory bowel disease, multiple sclerosis, myocardial ischemia, rheumatoid arthritis, transplant rejection and other inflammatory, autoimmune and immune disorders, comprising administering to a mammal an effective amount of a compound of claim
 1. 